CA1327402C - Method and apparatus for calculating arterial oxygen saturation based on plethysmographs including transients - Google Patents

Method and apparatus for calculating arterial oxygen saturation based on plethysmographs including transients

Info

Publication number
CA1327402C
CA1327402C CA000595258A CA595258A CA1327402C CA 1327402 C CA1327402 C CA 1327402C CA 000595258 A CA000595258 A CA 000595258A CA 595258 A CA595258 A CA 595258A CA 1327402 C CA1327402 C CA 1327402C
Authority
CA
Canada
Prior art keywords
transmittance
maximum
minimum
detected
optical signal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA000595258A
Other languages
French (fr)
Inventor
Robert T. Stone
Deborah A. Briggs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nellcor Inc
Original Assignee
Nellcor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nellcor Inc filed Critical Nellcor Inc
Application granted granted Critical
Publication of CA1327402C publication Critical patent/CA1327402C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1455Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
    • A61B5/14551Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/72Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7203Signal processing specially adapted for physiological signals or for diagnostic purposes for noise prevention, reduction or removal
    • A61B5/7207Signal processing specially adapted for physiological signals or for diagnostic purposes for noise prevention, reduction or removal of noise induced by motion artifacts

Abstract

Abstract A method and apparatus for improving the calculation of oxygen saturation by non-invasive pulse oximeters during transient conditions.
Transient conditions introduce artifactual errors into the detected optical signal because of changes in transmittance of the light with localized blood volume changes and as the average background oxygen saturation level of the patient's blood changes.
The invention relates to correcting the detected optical pulses by linear interpolation and rate of change techniques or by selective frequency filter-ing and compensating the detected optical signal using the filtered signal to provide accurate esti-mates of oxygen saturation during transient condi-tions.

Description

13 2 7 ~ 0 2 NEL-5B CANADA
., ' ,, :

, .
METHOD AND APPARATUS FOR CALCULATIN~
AP~TERIAL OXV~-EN SATURATION
BASED ON PLETEvsMoGRApHs INCLUDIN~ TRANSIENTS
This invention relates to non-invasive f' pulse oximetry and specifically to an improved method and apparatuC for calculating arterial saturation ~ during transient conditions based upon photoelectric ;~1 determination of a patient's plethysmograph. This specification is accompanied by a software appendix.
: .
Backqround of the Invention i Non-invasive photoelectric pulse oximetry has been previously described in U.S. Patent 4,407,290, U.S. Patent 4,266,554, U.S. Patent 4,086,915, U.S. Patent 3,998,550, U S. Patent , 3,704,706, European Patent Application No. 102,816 -~; published March 13, 1984, European Patent Application ; NO~ 104,772 published April 4, 1984, European Patent Application No. 104,771 published April 4, 1984, and ., 20 PCT International Publication WO 86/05674 published October 9, 1986. Pulse oximeters are commercially ::'! available from Nellcor Incorporated, Hayward, California, U.S.A., and are known as, for example, Pulse Oximeter Model N-100 (herein "N-100 oximeter") and Model N-200 (herein "N-200 oximeter").
. Pulse oximeters typically measure and dis-play various blood flow characteristics including ~, ., .

: :

" ~-,,~ . - ~ , . ~
::, :

~ ~` 2 1327402 ,. , - but not limited to blood oxygen saturation of hemo-globin in arterial blood, volume of individual blood ~ pulsations supplying the flesh, and the rate of blood 'i pulsations corresponding to each heartbeat of the patient. The oximeters pass light through human or animal body tissue where blood perfuses the tissue such as a finger, an ear, the nasal septum or the scalp, and photoelectrically sense the absorption of light in the tissue. The amount of light absorbed is then used to calculate the amount of blood con-stituent being measured.
' The light passed through the tissue is ~`, selected to be of one or more wavelengths that is absorbed by the blood in an amount representative of the amount of the blood constituent present in the blood. The amount of transmitted light passed ~, through the tissue will vary in accordance with the changing amount of blood constituent in the tissue and the related light absorption.
For example, the N-100 oximeter is a micro-processor controlled device that measures oxygen i saturation of hemoglobin using light from two light - emitting diodes ("LED's"), one having a discrete frequency of about 660 nanometers in the red light range and the other having a discrete frequency of ~'? about 925 nanometers in the infrared range. The ' N-~OO oximeter microprocessor uses a four-state clock , to~~provide a bipolar drive current for the two LED's so that a positive current pulse drives the infrared LED and a negative current pulse drives the red LED
to illuminate alternately the two LED's so that the incident light will pass through, e.g., a fingertip, and the detected or transmitted light will be detected - by a single photodetector. The clock uses a high strobing rate, e.g., one thousand five hundred cycles per second, to be easily distinguished from other light sources. The photodetector current ,~ . .
, :
, . . . . . .
; ~ , : ,', ' , ': ., .-,, .

,., :
; . . .

:
_3_ 13274 , changes ln response to the red and infrared light transmitted in sequence and is converted to a volta~e signal, amplified, and separated by a ~ two-channel synchronous detector -- one channel for :~- 5 processing the red light waveform and the other channel for processing the infrared light waveform.
`Y The separated signals are filtered to remove the , j, strobing frequency, electrical noise, and ambient ~ noise and then digitized by an analog to digital ;~i 10 converter ("ADC"). As used herein, incident light and transmitted light refers to light generated by the LED or other light source, as distinguished from i ambient or environmental light.
The light source intensity may be adjusted to accomodate variations among patients' skin color, flesh thickness, hair, blood, and other variants.
., , The light transmitted is thus modulated by the ; absorption of light in the variants, particularly the arterial blood pulse or pulsatile component, and is referred to as the plethysmograph waveform, or the optical signal. The digital representation of the optical signal is referred to as the digital ~`' optical signal. The portion of the digital optical ,":'''! signal that refers to the pulsatile component is ;; 25 labeled the optical pulse.
`' The detected digital optical signal is pro-; c ~ by the microprocessor of the N-100 oximeter lyze and identify optical pulses corresponding t~ arterial pulses and to develop a history as to pulse periodicity, pulse shape, and determined oxygen saturation. The N-100 oximeter microprocessor decides whether or not to accept a detected pulse as corre-~;, sponding to an arterial pulse by comparing the detected pulse against the pulse history. To be accepted, a detected pulse must meet certain pre-~- determined criteria, for example, the expected size of the pulse, when the pulse is expected to occur, and the expected ratio of the red light to infrared ,, ~ .
' , -.
~ .
.....

,, .

., ~ .

........

.:,.

,, . -. . .

~", I
r i 3 2 7 4 0 2 . light of the detected optical pulse in accordance with a desired degree of confidence. Identified individual optical pulses accepted for processing are used to compute the oxygen saturation from the ~i~ 5 ratio of maximum and minimum pulse levels as seen by .: the red wavelength compared to the maximum and minimum pulse levels as seen by the infrared wavelength, in accordance with the following equation:
Saturation = 100% x BR2 - R(BR1) -~ lo R(BO1 - BR1) + BR2 - BO2 :~ wherein .~ BOl is the extinction coefficient for `. oxygenated hemoglobin at light wavelength 1 (Infrared) . 15 BO2 is the extinction coefficient for ~ oxygenated hemoglobin at light wavelength 2 (red) .~ BR1 is the extinction coefficient for .. reduced hemoglobin at light wavelength 1 i BR2 is the extinction coefficient for reduced hemoglobin at light wavelength 2 light wavelength l is infrared light light wavelength 2 is red light ~ and R is the ratio of the optical density ;~z of wavelength 2 to wavelength 1 and is calcu-~. 25 lated as:
.i R = ~ max?/ min2]
~ ln [Imaxl/Imi l]
.' wherein ImaX2 is the maximum light transmitted at .; light wavelength 2 Imin2 is the minimum light transmitted at light wavelength 2 .~; ImaXl i.s the maximum light transmitted at , 35 light wavelength 1 ' Imin1 is the minimum light transmitted at light wavelength l .~

,.
.
, . .
, , .
... .
,,;, ~

,, ., ~ ~
- .. ~ ... .
. - ; .
", . ~

, ", ~

The various extinction coefficients are determinable by empirical study as are well known to those of skill in the art. For convenience of calculation, ~ the natural log of the ratios may be calculated by use of the Taylor expansion series for the natural log.
`^ Several alternate methods of processing `3 and interpreting optical signal data have been dis-closed in the patents and references cited above.
Normally, the relative oxygen content of the patient's arterial pulses remains about the same from pulse to pulse and the average background absorption between pulses remains about the same.
.
~ Consequently, the red and infrared light that is :iJ 15 transmitted through the pulsatile flow produces a ~; regularly modulated pletheysmograph waveform having periodic optical pulses of comparable shape and - amplitude and a steady state background transmittance.
; This regular pulse provides for an accurate determi-3 20 nation of the oxygen saturation of the blood based on the detected relative maximum and minimum trans-mittance of the red and infrared light.
Changes in the patient's local blood volume j at the optical detection site affect the absorption '- 25 of light. These localized changes often result from ; motion artifact or respiratory artifact which intro-- duce artificial pulses into the blood flow. For ;'~ e~ample, on each inhalation, the venus return is occluded slightly, which results in the background 30 intensity component of transmittance being decreased due to the relatively larger volume of blood at the ~ optical detection site. Exhalation allows the venus ,. return to expand, thereby decreasing the volume of , blood and increasing the background intensity com-- 35 ponent of transmittance. Consequently, the periodic x optical pulses ride on a background intensity com-ponent of transmittance that rises and falls with ., ,,~ .
. ~ .
; - .

, , . ~

~ . : . ,- .
., ' - .
-.~,. ,, ;

blood volume change. This background intensity com-; ponent variation, which is not necessarily related to changes in saturation, affects the pulse to pulse - uniformity of shape, amplitude and expected ratio of ~', 5 the maximum to minimum transmittance, and can affect the reliability and accuracy of the saturation ~ determination.
- In addition, there are times when the patient's background level of oxygen saturation undergoes transient changes, for example, when the - patient loses or reacquires oxygen exchange in the lungs while under gaseous anethesia. Consequently, , the detected red and infrared light transmittance changes and the detected plethysmograph waveform rises or falls over time with changes in the average ; oxygen saturation level in the patient's blood. The transient waveform distorts the pulse shape, ampli-tude, and the expected ratio of the pulses, which in turn affects the reliability and accuracy of the ~i 20 saturation determination.
-l Heretofore, with the foregoing known tech-niques for calculating arterial oxygen satuxation, it was known that, during changes in the background ~ intensity absorption component due to artifacts from ','~J' 25 changes in the patient's blood valume or transient ~;~ saturation changes, tha determined saturation value wa~-not accurate and that it would not become accurate 3 again until the average absorption (or transmittance) I leveI stabilized at the end of the artifact or the ^` 30 saturation transient.
J It also was known that saturation calcula-~ tions based upon transient optical signals provided ;. an over-estimation or under-estimation of the actual saturation value, depending upon the trend. The 35 transmittance of red light near the 660 nanometer wavelength increases as oxygen saturation increases.
'7 This results in the detected optical signal value :
, ., , - .

., :
" ~

.,, ;, ' ' ' ~ ' , . : -.'.' ' - ' ' :

~ ' ~7~ 1327402 having a smaller pulsatile amplitude, i.e., a smaller relative difference between the maximum and minimum ~'! of the pulse. In contrast, the transmittance of the infrared light near the 910 nanometer wavelength decreases as saturation increases, which causes the - infrared pulsatile amplitude - relative maximum to minimum - to increase. For both wavelengths, the transmittance changes with changing saturation are substantially linear and continuous in the range of clinical interest, i.e., oxygen saturations between `~ 50% and 100%.
The accuracy of the estimation is of particular concern during rapid desaturation, where average oxygen saturation drops rapidly, but the saturation determination based on the detected optical signals indicates a greater drop than has actually occurred. The determined saturation thus may actuate low limit saturation alarms on an oximeter device that can result in unnecessary and wasteful efforts to rescusitate a patient not in danger.
Applicants believe that the change in transmittance that occurs between the maximum trans-~ mittance time and minimum transmittance time is due ;~ to the difference in arterial pulsatile length of 25 pulse that has the same oxygen saturation. Because the pulsatile amplitude is quite small, typically le~ th~n 5% of the overall intensity change, any s ~ 1 change in overall or background transmittance, su¢h as slight changes in average blood saturation, ~l 30 can have a relatively large effect in the difference u in maximum and minimum intensity of the light levels.
Because the transmittance effect of changing oxygen saturation is opposite in direction for the red light at 660 nanometers than for infrared light at 910 35 nanometers, this can result in over-estimation of the pulsatile ratio during periods when saturation ., .

., - . ~ ; ,; ;

... .

' -8- 1327402 . ~
is decreasing, and under-estimation during periods when saturation is increasing.
It is therefore an object of this invention to provide a method and apparatus for compensating for the effects of transient conditions in the actual optically detected signal, thereby providing a more ;;; accur~te estimation of the actual oxygen saturation i value.
- It is another object of this invention to s 10 compensate for the effects of distortion in the detected oxygen saturation signal caused by arti-i facts due to localized blood volume changes.
; It is another object of this invention to compensate for the effects of distortion in the 15 detected oxygen saturation signal caused by transient saturation or blood volume artifact by using a deter-mined rate of change from pulse to pulse, including using interpolation techniques.
. It is another object of this invention to 20 compensate for the effects of distortion in the detected oxygen saturation signal caused by transient i saturation or blood volume artifact by using the low ;I frequency characteristics of the detected signal ~ values.
, . ~
;, 25 Summary of the Invention i~i This invention provides a method and ap-pa~atus for compensating for the artifactual errors in light transmittance during blood volume changes or transient saturation changes (hereinafter collec-30 tively referred to as "transient conditions"), ; thereby providing for improved accuracy of oxygen ,; saturation calculations during transient conditions.
The invention provides apparatus for processing the detected optical signals during transient conditions 35 so that the distortion in transmittance caused by the transient can be compensated. In one embodiment, ,, .'.
;,.,' , .

,, ~

, :, .

,', ' : . : ' ~ , "~'~' ' ' ' ' ' ' i~

-~ _9_ 1327~02 the compensation is made by converting a transient plethysmograph waveform into a steady state waveform whereby the ratio of the maximum and minimum trans-mittance can be determined based on the converted waveform and used in making the saturation deter-- mination. In an alternate embodiment, the compen-sation is made by dividing the detected optical signal by its low frequency components, i.e., the background and transient frequencies below the heart beat frequency, from which quotient signal the com-pensated maximum and minimum transmittance values can be detected and used in making the saturation determination. Throughout this application, the ,' words compensate, correct and adjust are intended to ;~/ 15 have the same meaning in that the actual detected value is converted to an artificial value that ~' results in a more accurate estimation of the actual 1s oxygen saturation of the patient.
;-~ In the preferred embodiment, the detected optical signals are obtained conventionally by pass-ing red and infrared light through a patient's blood ' perfused tissue, detecting the transmitted light ' which is modulated by the blood flow, and providing red and infrared detected optical signals that are preferably separately processed and optionally con-verted from analog to digital signals. The corre-I spcn*ing red and infrared digital optical signals - ar~ then processed in accordance with the present invéntion and the light modulation ratios are deter-; 30 mined based on the resulting corrected transmittance ; pulse and used to calculate oxygen saturation.
In one embodiment, the transient error is corrected by linear interpolation whereby the deter-mined maxima and minima for a first and second opti~
cal pulses are obtained, the second pulse following the first and preferably immediately following the first pulse, and the respective rates of change in '' ' ' ' . . .
. ~ .
, "' ' ' ' ` ~

~ `
-lO- 1327~02 the transmittance of that wavelength is determined from the maximum transmittance point of the first detected pulse to the second detected pulse. The determined rates of change are then used to compen-sate any distortion in the detected transmittance ofthe first detected pulse introduced by the transient in accordance with the following algorithm:
Vmax(n)* = Vmax(n) - [Vmax(n) -... .
Vmax(n+1)] [tmax(n)-tmin(n)~]
[tmax(n+1)-tmax(n)]
/
where tmax(n) is the time of occurence of the detected maximum transmittance at the n maximum; tmin(n) is the time of occurrence of the detected minimum trans-mittance of the wavelength at the n minimum; Vmax(n) ~,15 is the detected optical signal maximum value at the maximum transmittance of the wavelength at the n maximum; Vmax(n)* is the corrected value, for n being the first optical pulse, and n+l being the second optical pulse of that wavelength.
By application of the foregoing linear interpolation routine, the detected maximum trans-r-~ mittance value at t = n can be corrected, using the detected values detected at the next coming pulse ~ t = n+l, to correspond to the transmittance value - 25 than~would be detected as if the pulse were detected at~3teady state conditions. The corrected maximum vaiue and the detected (uncorrected) minimum value thus provide an adjusted optical pulse maximum and minimum that correspond more closely to the actual oxygen saturation in the patient's blood at that time, notwithstanding the transient condition. Thus, using the adjusted pulse values in place of the detected pulse values in the modulation ratio for - calculating oxygen saturation provides a more accur-" !
'~''"`

..
, . , .
~ , . .
" ' ~ ' ' ' ,'. . ' , ; ~ . , '' ' ' ' ' ' ' ' ' ' ' ' ' "' .' . ~
"' ' ' ~ .

'' .

~ ~', ~ , , ,' ' ' ... . .

ate measure of oxygen saturation than would other-wise be obtained during transient operation.
In the preferred embodiment, the transient error is corrected by linear interpolation whereby the determined maxima and minima for a first and second optical pulses are obtained, the second pulse following the first and preferably immediately follow-ing the first pulse, and the respective rates of change in the transmittance of that wavelength is determined from the minimum transmittance point of the first detected pulse to the minimum of the second detected pulse. The determined rates of change are then used to compensate for any distortion in the detected minimum transmittance of the second detected pulse introduced by the transient in accordance with the following algorithm:
Vmin(n)* = Vmin(n-1) + ~Vmin(n) -Vmin(n-l)] x ~ 1))]
[tmln(n)-tm ~ = ~
~ç 20 where tmax(n) i8 the time of occurence of the detected ;i maximum transmittance at the n maximum; tmin(n) is the time of occurrence of the detected minimum trans-s mittance of the wavelength at the n minimum; vmin(n) is the detected optical signal minimum value at the 25 minimum transmittance of the wavelength at the n min~um; Vmin(n)* is the corrected value, for n being th~`-second optical pulse, and n-l being the first op~ical pulse of that wavelength.
By application of the foregoing linear 30 interpolation routine, the detected minimum trans-mittance value at t = n can be compensated, using the detécted values detected at the preceding pulse t = n-1, to correspond to the transmittance value . that would be detected as if the pulse were detected at steady state conditions. The compensated minimum value and the detected (uncompensated) maximum value .~ ~

' ' .
~'' , .-`.i, , .
. .
, , ,. . .

, -12- 1327402 thus provide an adjusted optical pulse maximum and minimum that correspond more closely to the actual o~ygen saturation in the patient's blood at that time, notwithstanding the transient condition. Thus, using the adjusted pulse values in place of the detected pulse values in the modulation ratio for calculating oxygen saturation provides a more accur-ate measure of oxygen saturation than would other-wise be obtained during transient operation.
As is apparent from the algorithms, during steady state conditions the compensated value is equal to the detected value. Therefore, the linear interpolation routine may be applied to the detected -~ signal at all times, rather than only when transient conditions are detected. Also, the algorithm may be ;l- applied to compensate the detected other minimum or ~ maximum transmittance values by appropriate adjust-'1 ment of the algorithm terms.
The amount of oxygen saturation can be then determined from this adjusted optical pulse signal by determining the relative maxima and minima as compensated for the respective wavelengths and using that information in determining the modulation ratios of the known Lambert-Beers equations. Indeed, the present invention may be applied to any pulsa-;~ tile flow detected by light absorption or trans-mittance corresponding to the flow having transient cha~ges or conditions, whether based on the occur-rence of individual pulses or averaged pulses.
i 30 Applicants also have discovered that the ; detected optical signals can be processed and cor-rected in accordance with the present invention by using the frequency characteristics of the detected optical signal. The optical signals for a given wavelength corresponding to the pulsatile arterial blood flow have spectral components including a zero frequency at the background transmittance intensity ..... .
:', .,, ~

,, .

,. . .

,, - . , :
, ~, .

, , . .: : . , ~, ` , -13- 1327~02 ;; level, a fundamental frequency at the frequency of the beating heart, and additional harmonic frequencies at multiples of the fundamental frequency. Noise, spurious signals, and motion artifact that appear in s the detected optical signal have frequencies that spread across the spectrum. Transient changes to the background transmittance intensity appear as low fre-guency signals that are below the heart rate frequency.
l In accordance with an alternate embodiment ;j 10 of the invention, for each of the wavelengths of the , light transmitted, the detected optical signal is -`~i split into two portions. For one of the portions, the frequency domain corresponding to the frequency components below the range of the measured heart rate, including the background and any transient frequency component~, is separated from the higher . ., i frequency components. Applicants have discovered ' that if the first domain is separated so that no phase shifting occurs relative to the other portion `, 20 of the unfiltered detected signal, the first domain signal can be divided into the unfiltered signal, thereby to correct for changes in the pulsatile amplitude in the unfiltered signal portion on a con-tinuous basis, for the background transmittance dur-ing steady state conditions, during artifactual blood volume changes and transient saturation tranæmittance chfl~ges. It may be appropriate to amplify the separated or filtered signal, the unfiltered signal, or the resulting quotient signal to obtain an ad-justed signal having an appropriate amplitude andresolution for making the saturation determination.
- Separation of the low frequency components may be realized in either the time domain or the frequency domain. In the time domain, the separa-tion may occur by passing one portion of the analog -~ detected optical signal through conventional elec-tronic circuits such as low paæs filters configured :
,.

. , .

,,~ .
. ~ .. . ..
'~,'" ' ' '' : ~
., , .' , , , .

~, . , -14- 1327~02 to avoid any phase shifting to obtain a filtered ~, signal having only the background and low frequency ~ components, and then passing the filtered signal and 3 , a portion of the unfiltered analog detected signal 5 into dividing amplifiers to divide the low passed ~ignal into the unfiltered signal in phase. This process results in a compensated optical signal that can be processed as if it were the actual detected optical signal to determine the relative maxima and lO minima of the detected pulses for the satuation calculations. Alternately, the detected optical r`, signal may be digitized and processed using digital - signal processing techniques to filter the detected-signal and divide the filtered signal into the 15 unfiltered detected signal.
Digital processing techniques also may be ~ applied to process the detected optical signal in i;l the frequency domain by the application of well-;~ known Fourier Transforms. In this embodiment, a `, 20 time-measure of the detected optical signal for a predetermined number of heartbeats is collected and ''i,.~! transformed into its spectral components. The fre-quency components are then separated into two domains, the first domain including spectral compon-~:, 25 ents below the measured heart rate so that it ~, includes the zero frequency spectral components of ii t~ background intensity and any gradual changes in ,~ th~background intensity corresponding to the ,.~ transient condition, and the second domain being above the first so that it includes the spectral ~; components of the fundamental and higher order harmonics of the fundamental for the number of heartbeats in the sample. The separation must occur so that no phase shifting occurs in the first domain. Then, the filtered first domain spectral components can be transformed back into the time domain, into the background and changing background ' : , , .,,, - , , - .
.. - . , " - : . . ..
.-, ~ . .
. ' ' , , -15- ~327402 intensity, and divided into the unfiltered detected pulsatile waveform in phase thereby compensating ~- for transient conditions in the unfiltered waveform.
As the time-measure is updated to include the ~, 5 patient's current condition, the divison of the unfiltered waveform by its low frequency components ~" thus corrects the pulsatile amplitude for changes in the background transmittance on a continuous basis.
^~ Thereafter, the oxygen saturation calculation can be - 10 based upon the compensated quotient waveform.
;~ Similar to the preferred embodiment, this frequency compensation embodiment may be used all the time.
The apparatus of the preferred embodiment ~;~ 15 present invention can be used for either time domain or freguency domain transient correction, and includes inputs for the detected optical signals, ; an analog to digital converter for converting the analog plethysmograph signal to the digital optical signals (unless the plethysmograph signals are pro-vided in digital form), and a digital signal pro-` cessing section for receiving the digital signals and processing the digital detected optical signal :i in accordance with one of the foregoing analysis i 25 techniques of the present invention, including a -- microprocessor, memory devices, buffers, software ontrolling the microprocessor, and display ~i de~ices.
''',7 ~'' In its context, the apparatus of the present - 30 invention is a part of an oximeter device which has the capability to detect the red and infrared light ;~ absorption. In the preferred embodiment, the . apparatus of this invention is a part of the Nellcor N-200 oximeter which includes a 16 bit microprocessor . 35 manufactured by Intel Corporation, Model No. 8088, software for controlling the microprocessor to perform the operations of the preferred embodiment of the '-.

..

:~
:' :
;., .
,, .

:

` , -16- 1 3 2 7 4 0 2 time domain analysis techniques of present invention ~ (in addition to the conventional oximeter functions), : and has structure and processing methods that are unrelated to the present invention, and therefore are not discussed herein. The software could be ~,r.`' modified to perform the frequency domain analysis techniques of the present invention.
~i Brief DescriPtion of the Drawinqs Fig. 1 is a block diagram of the apparatus ;~ 10 of this invention and the apparatus associated with the present invention.
i~ Fig. 2 is a detailed circuit schematic of , the saturation preamplifier in the patient module of Fig. 1.
Figs. 3A and 3B are a detailed circuit schematic of the saturation analog front end circuit ,~, of Fig. 1.
Fig. 4 is a detailed circuit schematic of the LED drive circuit of Fig. 1.
'~ 20 Figs. 5A and SB are a detailed circuit schematic of the analog to digital converter section ,' of Fig. 1.
Figs. 6A, 6B and 6C are a detailed circuit schematic of the digital signaI processing section of Fig. 1.
Figs. 7a, 7b, 7c, 7d, 7e, and 7f are graphical representations of detected optical ^ signals during steady state and transient condi-tions.
Detailed Descriptlon of the Preferred Embodiment Referring to Fig. 1, the preferred embodi-' ment of the present invention relates to the apparatus for processing the detected analog optical plethysmo-graph signal and comprises portions of analog to digital conversion section ("ADC converter") 1000 , ;~; . , - :
',,~' ' ,~;, .
., _ , - . _ .. . . . .

:: :
. ~, : . , : i i , ; . . . : . . ,: , , ; and digital signal processing section ("DSP") 2000, including the software for driving microprocessor 2040, which processes the digitized optical signals in accordance with the present invention to determine ; 5 the oxygen saturation of hemoglobin in arterial blood.
Associated with the invention, but not forming a ' part of the invention, is the apparatus for obtaining ; the detected analog optical signals from the patient ~ that is part of or is associated with the commercially ; 10 available Nellcor N-200 Pulse Oximeter. Such appa-ratus include plethysmograph sensor 100 for detecting optical signals including periodic optical pulses, patient module 200 for interfacing plethysmograph sensor 100 with saturation analog front end circuit 300, and saturation analog circuit 30~ for processing the detected optical signals into separate red and infrared channels that can be digitized. The N-200 oximeter also includes LED drive circuit 600 for ~, strobing the red and infrared LEDs in plethysmograph sensor 100 at the proper intensity to obtain a detected optical signal that is acceptable for ~ j ; processing, and various regulated power supplies . J, (not shown) for driving or biasing the associated 1 circuits, as well as ADC 1000 and DSP 2000, from line current or storage batteries.
~- The associated elements are straightforward cirGuits providing specified functions which are ~ within the skill of the ordinary engineer to design i~' an~ build. The associated elements are briefly described here, and reference is made to the corre-, sponding detailed schematics in the Figures and circuit element tables set forth below, to place the apparatus of the present invention in its operating context in the preferred embodiment.
In the preferred embodiment, the invention requires two input signals, the two plethysmograph - or detected optical signals at the first and second . ., ~ ., .
,. . .
, . . . .
,:~
. . .
":
,,, ' . . .

., . . :
. . , ... . .

~ 1327402 wavelengths (e.g., red and infrared). More than two ~` wavelengths may be used. If analog signals are pro-vided, they must be within or be adjusted by, for example, offset amplifiers to be within the voltage input range for the ADC. In circumstances where the signals have been digitized already, they must be bit compatible with the digital signal processing devices, DSP.
The plethysmograph signal is obtained in a conventional manner for a non-invasive oximeter, typically by illuminating the patient's tissue with red and infrared light in an alternating fashion, for example, in the manner described above for the ~i N-100 oximeter. Referring to Fig. 1, sensor circuit 100 has red LED 110 and infrared LED 120 connected ; in parallel, anode to cathode, so that the LED drive ~:-! current alternately illuminates one LED and then the other LED. Circuit 100 also includes photodetector 130, preferably a photodiode, which detects the level of light transmitted through the patient's tissue, e.g., finger 140, as a single, analog optical signal -1 containing both the red and infrared light plethys-- mographic, detected optical signal waveforms.
Referring to Figs. 1, and 2, patient module 200 inciudes preamplifier 210 for preamplifying the analog detected optical signal of photodetector 130.
Pre W lifier 210 may be an operational amplifier ' co~igured as a current to voltage converter, biased by`a positive voltage to extend the dynamic range of the system, thereby converting the photocurrent of photodiode 130 into a usable voltage signal.
Patient module 200 also includes leads for passing -~ the LED drive volt~ges to LEDs 110 and 120.
Referring to Figs. 1, 3A, and 3B, satura-- 35 tion analog front end circuit 300 receives the ;~ analog optical signal from patient module 200 and filters and processes the detected signal to provide ' , ~ , , , . :
~, . ~ , ; .
, :' . ' '` ~ ` '-, : ~. -.

,.................................................. .

-19- i327~2 separate red and infrared analog voltaye signals ` corresponding to the detected red and infrared opti-cal pulses, The voltage signal is passed through low pass filter 310 to remove unwanted high frequency components above, for example, 100 khz, AC coupled through capacitor 325 to remove the DC component, passed through high pass filter 320 to remove any unwanted low frequencies below, for example, 20 hertz, ~- and passed through buffer 320 and passed through programmable gain stage 330 to amplify and optimize the signal level presented to synchronous detector 340.
Synchronous detector 340 removes any common mode signals present and splits the time multiplexed optical signal into two channels, one representing the red voltage signals and the other - representing the infrared voltage signals. Each signal is then passed through respective filter chains having two 2-pole 20 hertz low pass filters 20 350 and 360, and offset amplifier 370 and 380. The filtered voltage signals now contain the signal ` information corresponding to the red and infrared detected optical signals. Additionally, circuits for use in preventing overdriving the amplifiers in - 25 saturation circuit 300 may be applied, for example, ~- level-sensing circuits 312 and 314 (located before and~after low pass filter 310 respectively) for ~, indicating unacceptable LED drive current, and level sensing circuit 315 (located after programmable gain amplifier 330) for indicating unacceptable input , amplifier gain setting.
Referring to Figs. 1, 5A, and 5B, ADC lO00 provides the analog to digital conversions required by the N-200 oximeter. The aforementioned two voltage signals, the red detected optical signal and the ;~ infrared detected optical signal from patient module 200, are input to ADC 1000. These signals are con-, ., . ~ , ~ , ~; . . : .
,, , ~, , .. , ~ , . , ... ,, ,. ., . ,. , . ~ .
.
, '.:, ', ' ` .' "
.

-20- 1~27402 ventionally multiplexed and digitized by an expanded range 12-bit analog-to-digital conversion technique, yielding 16-bit resolution. The input signals are : passed through multiplexor 1010 and buffer amplifier 1020. The converter stage includes offset amplifier 1030 and programmable gain circuitry 1040 which allows a portion of the signal to be removed and the remainder to be further amplified for greater reso-lution, sample and hold circuit 1050, comparator 1060, and 12-bit digital to analog converter 1080.
The buffered signal is passed through offset ampli-fier 1030 to add a DC bias to the signal wherein a portion of the signal is removed and the balance is amplified by being passed through programmable gain circuitry 1040 to improve the resolution. The amplified signal is then passed through sample and hold circuit 1050, the output of which is fed to one : input of comparator 1060. The other input of com-: parator 1060 is the output of digital to analog ("DAC") converter 1080 so that when the inputs to comparator 1060 are the same, the analog voltage at . the sample and hold circuit is given the correspond-ing digital word in DAC converter 1080 which is then stored in an appropriate memory device as the . 25 digitized data for the sample and the next sample is . sent So sample and hold circuit 1050 to be diqitiz-ed..
- Referring to Figs. 1, 4, 5A, 5B, 6A, 6B
-:. and 6C, DAC 1080 also generates the sensor LED drive :~'! 30 voltages, under the control of microprocessor 2040, using analog multiplexor 610, which separates the incoming analog signal into one of two channels for respectively driving the red and infrared LEDs, having respective sample and hold circuits 620 and 630, and : 35 LED driver circuit 640 for converting the respective analog voltage signals into the respective positive '.
. .
.

,, .
~,............................................. . . .
" ' ' . ! ' , ~ :
~' , ' -21 ~327~02 and negative bipolar current signals for driving LEDs 110 and 120.
Alternate technigues of converting the analog signals to digital signals could be used, for example, a 16-bit analog to digital converter.
Referring to Figæ. 1 6A, 6B, and 6C, DSP
2000 controls all aspects of the signal processing operation including the signal input and output and intermediate processing. The apparatus includes 16-bit microprocessor 2040 and its associated sup-^ port circuitry including data bus 10, random access memory (RAM) 2020, read only memory (ROM) 2030, a conventional LED display device 2010 (not described in detail), system timing circuit 2050 for providing ` 15 the necessary clock synchronizing signals. In the - -preferred embodiment, microprocessor 2040 is a model 8088 microprocessor, manufactured by Intel Corpora-tion, Santa Clara, California. Alternate micropro-cessors may be used, such as any of model nos. 8086, 80186, and 80286, also made by Intel Corporation.
The N-200 oximeter incorporating the pre-~, sent invention is designed to determine the oxygen saturation in one of two modes, an unintegrated mode wherein the oxygen saturation determination is made :~ 25 on the basis of pulses detected in the optical pulse signal that are determined to be optical pulses in accordance with conventional pulse detection tech-niques, and in an ECG synchronization mode wherein the determination is based on enhanced periodic data `~ 30 obtained by processing the detected optical signal `~ and the ECG waveform of the patient in accordance with an invention that is not a part of the present invention.
The present invention applies to the cal-culation of saturation based on detecting maximum J'.~ and minimum transmittance of two or more wavelengths, whether the determination is made pulse by pulse '~i, ',' , . .

, . : ..

, ,, , , ... ~ ~ . . .

., , , ~ :

, -22- ~327402 (the unintegrated mode) or based on an averaged or composite pulse that is updated with the occurrence of additional pulses to reflect the patient's actual condition (the ECG synchronized mode).
Interrupt programs control the collection and digitization of incoming optical signal data.
As particular events occur, various software flags are raised which transfer operation to various routines that are called from a main loop processing routine.
The detected optical signal waveform is sampled at a rate of 57 samples per second. When `~ the digitized red and infrared signals for a given portion of detected optical signals are obtained, they are stored in a buffer called DATBUF and a soft-ware flag indicating the presence of data is set.
This set flag calls a routine referred to as MUNCH, which processes each new digitized optical signal waveform sample to identify pairs of maximum and ^ 20 minimum amplitudes corresponding to a pulse. The MUNCH routine first queries whether or not there is ' ECG synchronization. If there is ECG synchroniza-1 tion, then the MUNCH routine sbtains the enhanced x composite pulse data in the ECG synchronization mode.
Otherwise, MUNCH obtains the red and infrared optical signal sample stored in DATBUF, in the unintegrated mod~. The determined maximum and minimum pairs are ; th~n sent to a processing routine for processing the pairs. Preferably, conventional techniques are used for evaluating whether a detected pulse pair is acceptable for processing as an arterial pulse and ; performing the saturation calculation, whether the : pulse pair is obtained from DATBUF or from the enhanced composite pulse data.
The MUNCH routine takes the first coming pulse data and determines the maximum and minimum transmittance for each of the red and infrared . .
,, .

.. : ~ ,, , - ~\

detected optical signals, takes the second coming pulse data, and determines the relative maximum and minimum transmittance. The routine for processing the pairs applies the aforementioned algorithm to 5 the first and second pulse data of each wavelength and determines the corrected minimum transmittance for the second pulse each wavelength. Then the oxygen saturation can be determined using the corrected minimum and detected maximum transmittance for the 10 second pulses of the red and infrared optical signals.
The application of the present invention and the pair processing routine correction is demon-strated by the following comparative examples, with !~ reference to Figs. 7a, 7b, 7c, 7d, 7e and 7f and the 15 software appendix. 5 Examvle I
Figs. 7a and 7b show representative plethys-mograph waveforms for a patient's steady state condi-tion for the red and infrared detected optical 20 signals. Vmaxr(n) equals 1.01 volts, and Vminr(n) r,~' equals 1.00 volts, for n = 1,2, and 3 pulses. Vmin(n) is the detected optical signal minimum value at the minimum transmittance at the n pulse minimum. The modulation ratio for the maxima and minima red signal ,~ 25 is - Vmaxr(n) = 1 Olv = 1.01 ^- Vmi ~ nj l OOv For the infrared wavelength, Vmaxi(n) = l.Olv and Vmini(n) = l.OOv and the determined modulation ratio 30 also is 1.01.
U~ing these determined modulation ratios n the formula for calculating the ratio R provides:
R = ln fVmaxr(n)/Vminr(n)l = .01 = 1.00 ln [Vmaxl(n)/Vmini(n)] .01 35 A determined R = 1 corresponds to an actual saturation value of about 81% when incorporated into the afore-. ' .

: . . ... . . .

,~ . . . -. ~ ~ , . .

~ -24- 1327402 .~ , mentioned saturation equation. A saturation of 81%
; corresponds to a healthy patient experiencing a degree ~- of hypoxia for which some corrective action would be taken.
Example I I
Figs. 7c and 7d correspond to representa-tive plethysmographic waveforms for a patient during desaturation or decreasing saturation transient con-ditions for the red and infrared detected optical signals having optical pulses n = 1, 2, and 3. How-; ever, in this transient example it is known that at n = 1, the actual saturation of the patient is very ,?~, close to that during the steady state conditions in the Example I. In this transient example, the detected values are as follows:
For both the red and infrared signals:
tmax(l) = 1.0 secs.
tmin(l) = 1.2 secs.
tmax(2) = 2.0 secs.
tmin(2) = 2.2 secs.
tmax(3) = 3.0 secs.
tmin(3) = 3.2 secs.
For the red optical signals:
Vmaxr(l) = 1.012v . 25 Vminr(l) = l.OOOv Vmaxr(2) = 1.002v ^ ~ ~ Vminr(2) = O.990v ~ Vmaxr~3) = 0.992v Vminr(3) = 0.980v For the infrared optical signals:
Vmaxi(1) = 1.008v Vmini(l) = l.OOOv Vmaxi(2) = 1.018v , Vmini(2) = l.OlOv Vmaxi(3) = 1.028v ~ Vmini(3) = 1.020v.
`::
,.:
~. , ~ . - .

, .
. , , .,;: " , ~

, ~ , - ..
' ' ' ' ~ . , , . ~ .. . . ~ ;
: . ., ,: :

- Calculating the oxygen saturation ratio R
at n = 1, using the detected optical signals pro-vides the following:
R = ln[Vmaxr(l)/Vminr(l)]/ln[Vmaxi~l)/Vmini(l)]
= ln[l.012/1.0003/ln[1.008/1.000]
= ln[1.012]/ln[1.008]
= .012/.~08 = 1.5 Thus, the determined saturation ratio R of 1.5 based lo on the detected transmittance corresponds to a cal-culated oxygen saturation of about 65% for the patient, which corresponds to severe hypoxia in an otherwise healthy patient. This contrasts with the known saturation of about 81% and demon~trates the magnitude of the under-estimation of the oxygen saturation (over-estimation of desaturation) due to the distortion in transmittance of the red and - infrared light caused by transient conditions.
Applying the present invention to correct ,~ 20 the distorted maximum transmittance point of the detected red optical signal during the transient condition, we find the following:
Vmaxr(l)* = Vmax(l) - [Vmax(l) -. .
... ~, Vmax(2)]x~n(1) ` 25 [tmax(2)-tmax(l)~
` = 1.012 - [1.012 - 1.002]x[1.0 - 1.2]/[1.0 - 2.0]
,, . : = 1 . 010 ~ an~ correspondingly for the maximum transmittance -~ of the detected infrared optical signal we find:
Vmaxi(l)* = 1.008 - [1.008 - 1.018] x [1.0 - 1.2]/[1.0 - 2.0]
= 1.010 ~ Thus, by replacing Vmaxr(n) with Vmaxr(n)* and - replacing Vmaxi(n) with Vmaxi(n)* in the calcula , 35 tions for determining oxygen saturation ratio R we find:

., ~ .

. "
" , , , , , , -:~ , . .
,, . . . . , , ., ,, ~ ~ , .
~, , . ' ~;' . ' ' ' ',: .,' ' "'. ' ' ' - : . .

R = ln[Vmaxr(1)*/Vminr(1)]/ln[Vmaxi(l)*~Vmini(1)~
= ln[1.010/1.00]/ln[l.010/1.00]
-., = .01/.01 = 1Ø
Thus, basing the saturation calculations on the corrected maximum transmittance values and ; the detected minimum transmittance values, the cor-- rected R value corresponds to the same R for the ; - steady state conditions and the actual oxygen satura-~ 10 tion of the patient.
;~ :
L Example III
~.
Figs. 7e and 7f correspond to representa-tive plethysmographic waveforms for a patient during ;`increasing saturation transient conditions for the -~15 red and infrared detected optical signals having optical pulses n = 1, 2, and 3. However, in this transient example it is known that at n = 1, the actual saturation of the patient is very close to ~that during the conditions in the steady state `,'!20 Example I. In this transient example, the detected values are as follows:
For both the red and infrared signals:
tmax(1) = 1.0 secs.
tmin(1) = 1.2 secs.
tmax(2) = 2.0 secs.
~~ tmin(2) = 2.2 secs.
tmax(3) = 3.0 secs.
tmin(3) = 3.2 secs.
; For the red optical signals:
Vmaxr(1) = 1.008v Vminr(1) = l.OOOv Vmaxr(2) = 1.018v Vminr(2) = l.OlOv Vmaxr(3) = 1.428v Vminr(3) - 1.020v ..
. .

: . .

,;,, ,, ,'J. . ~ ~ ':

'~`' ' , ' ' ' .
~ . , ' "" ' For the infrared optical signals:
Vmaxi(1) = 1.012v Vmini(l) = l.OOOv Vmaxi(2) = 1.002v Vmini(2) = .99Ov ` Vmaxi(3) = .992v ~ Vmini(3) = .980v.
`,~ Calculating the oxygen saturation ratio R
at n = 1, using the detected optical signals pro-~- 10 vides the following:
R = ln[Vmaxr(l)/Vminr(l)]/ln[Vmaxi(l)/Vmini(1)]
= ln[1.008/1.000]/ln[1.012/1.000]
'.'';!`' = ln[l.008]/ln[1.012]
= .008/.012 ~' 15 = .667 Thus, the determined saturation R of .667 corresponds to a calculated oxygen saturation of about 95% for ,~ the patient which corresponds to a satisfactorily ~ oxygenated patient breathing room air. This contrasts ,',,~A, 20 with the known saturation of about 81% and demon-strates the magnitude of the over-estimation of saturation due to the distortion in transmittance of the red and infrared light caused by transient ~l conditions.
;~ 25 Applying the present invention to correct the distorted maximum transmittance point of the ~, detected red optical signal during the transient condition we find:
~; ,, .' Umaxr(l)* = Vmax(1) - [Vmax(1) -~' 30 Vmax(2)]x[tmaX(1)-tmin(1)1 ttmax(2)-tmax( r~
, = 1.008 - [1.008 - 1.018] x [1.0 - 1.2]/[1.0 - 2.0]
, ,~, ' = 1.010 - 35 and correspondingly for the detected infrared optical signal:

.
. . .
, . . .
~, .. .
.. . .

, ,~. ~.; , . . . -, j , . . .
:
, . -,, .

, -28- 1327402 Vmaxi(1)* = 1.012 - [1.012 - 1.002]x[1.0 - 1.2]/
[l.O - 2.0 = 1.010 ` Thus, by replacing Vmaxr(n) with Vmaxr(n)* and replacing Vmaxi(n) with Vmaxi(n)* in the calcula-~, tions for determining oxygen saturation ratio R we find:
R = ln[Vmaxr(1)*/Vminr(1)]/ln[Vmaxi(1)*fVmini(1)]
= ln[1.010/1.00]/ln[1.010/1.00]
: 10 = .01/.01 , = 1Ø
Thus, basing the saturation calculations on the corrected maximum transmittance values and the detected minimum transmittance values, the ,` 15 corrected R value corresponds to the same R for the , steady state conditions and the actual oxygen satura-tion of the patient.
Example IV
- Figs. 7c and 7d also correspond to repre-sentative plethysmographic waveforms for a patient during desaturation or decreasing saturation tran-- sient conditionis for thie red and infrared detected optical signals having optical pulses n = 1, 2, ~! and 3. However, in this transient example it is known that at n = 2, the actual saturation of the p ~ ènt i8 very close to that during the steady : state conditions in the Example I. In this tran-~ sient example, the detected values are as follows:
, ., ,s For both the red and infrared signals:
tmax(1) = 1.0 secs.
tmin(l) = 1.2 secs.
tmax(2) = 2.0 secs.
tmin(2) = 2.2 secs.
tmax(3) = 3.0 secs.
~ 35 tmin(3) = 3.2 secs.

'"'i . i ..:i ,': :.......................... .
~, , , . . .
.;,. ~

, ,.,;, . . .. .
,~ ' ' , .
~', , :
~ ` -29- 1327~02 For the red optical signals:
Vmaxr(l) = 1.022v Vminr(l) = 1.008v ~; Vmaxr(2) = 1.012v Vminr(2) = 0.998v vmaxr(3) = 1.002v ' Vminr(3) - 0.988v ; For the infrared optical signals:
Vmaxi(l) = 1.002v Vmini(l) = 0.992v ; Vmaxi(2) = 1.012v Vmini(2) = 1.002v Vmaxi(3) = 1.022v ;,:
Vmini(3) = 1.012v Calculating the oxygen saturation ratio R
` at n = 2, using the detected optical signals pro-vides the following:
R = ln[Vmaxr(2)/Vminr(2)]/ln[Vmaxi(2)/Vmini(2)]
= ln[l.012/.998]/ln[1.012/1.002]
, 20 = .01393/.009g ; = 1.4 Thus, the determined saturation ratio R of 1.4 based on the detected transmittance corresponds to a cal-culated oxygen saturation of about 51% for the patient, which corresponds to severe hypoxia in an otherwise healthy patient. This contrasts with the saturation of about 81% and demonstrates the ,. . .j , , . ~ .
~ ~ ~ ude of the under-estimation of the oxygen - saturation (over-estimation of desaturation~ due to -~ 30 the distortion in transmittance of the red and infrared light caused by transient conditions.
Applying the preferred embodiment of the present invention to correct the distorted minimum ~^= transmittance point of the detected red optical signal during the transient condition, we find the following:
.~

','.', .

"", ., -, :,' . . ~ ~ . , , ,~ ,.~ , ,, , .
i ~, . .
. . . .

--`; 1327~02 Vminr(2)* = Vmin(2) + [Vmin(2) -, .
Vmin(l)]x[tmax(2)-~min(1)]
[tmin(2)-tmln(l)]
= 1.008 + [.998 - 1.0~8~x[2.0 - 1.2]/[2.2 - 1.2]
5 = 1.0 and correspondingly for the minimum transmittance of the detected infrared optical signal we find:
vmini(2)* - .992 ~ [1.002 - .992] x .8 . .
` = 1.0 ,~ 10 Thus, by replacing Vminr(n) with Vminr(n)* and ;;~ replacing Vmini(n) with Vmini(n)* in the calcula-tions for determining oxygen saturation ratio R we find:
R = ln[Vmaxr(2)/Vminr(2)*]/ln[Vmaxi(2)/Vmini(2)*]
= ln[l.O12/1.0]/ln~1.012/1.0]
= 1Ø
Thus, basing the saturation calculations on the corrected minimum transmittance values and the detected maximum transmittance values, the cor-rected R value corresponds to the same R for thesteady state conditions and the actual oxygen satura-- tion of the patient.
, ...
;~ Exam~le V
:; Figs. 7e and 7f also correspond to repre-~ 25 sentative plethysmographic waveforms for a patient : durinq increasing saturation transient conditions ` for the red and infrared detected optical signals having optical pulses n - 1, 2, and 3. However, in this transient example it is known that at n = 2, the actual saturation of the patient is identical to , that during the conditions in the steady state ; example. In this transient example, the detected ;; values are as follows:
, ...
.., ,"
.~ s .~

, ~, ., s , ., . ~
, .~, , ., ~

., ~ , ~ ~ .- .
;~,,,: . .

.~
,~.. 'i ~

. "

' For both the red and infrared signals:
tmax(l) = 1.0 secs.
tmin(1) = 1.2 secs.
tmax(2) = 2.0 secs.
s tmin(2) = 2.2 secs.
, tmax(3) = 3.0 secs.
tmin(3) = 3.2 secs.
- For the red optical signals:
Vmaxr(1) = 1.002v Vminr(1) = 0.992v ~^~ Vmaxr(2) = 1.012v Vminr(2) = 1.002v Vmaxr(3) = 1.022v - Vminr(3) = 1.012v For the infrared optical signals:
Vmaxi(1) = 1.022v Vmini(1) = 1.008v Vmaxi(2) = 1.012v Vmini(2) = .998v Vmaxi(3) = 1.002v "''7 Vmini(3) = .988v ,~,!, Calculating the oxygen saturation ratio R
~` at n = 2, using the detected optical signals pro-- vides the following:
~, 25 R = ln[Vmaxr(2)/Vminr(2)]jln[Vmaxi(2)/Vmini(2)]
= ln[l.012/1.002]/ln[1.012/.988]

Thu~, the determined saturation R of .713 corresponds to a calculated oxygen saturation of about 92~ for the patient which corresponds to a mildly hypoxic patient breathing room air. This contrasts with the known saturation of about 81% and demonstrates the magnitude of the over-estimation of saturation due to the distortion in transmittance of the red and ,~ 35 infrared light caused by transient conditions.
~ .

;,,, ., .
.
., ~
,'''' , ,...
., . ~
v .,~

., , . ~ -;, , Applying the preferred embodiment of the present invention to correct the distorted minimum transmittance point of the detected red optical signal during the transient condition we find:
Vminr(2)* = Vmin(1) + [Vmin(2) -Vmin(l)]x[tmax(2)-tmin~1)]
~tmin(2)-tmin(l)]
= .992 + [1.002 - .992] x [2.0 - 1.2]/
[2.2 - 1.2]]
',' 10 = 1.0 and correspondingly for the detected infrared optical signal:
Vmini(2)* = 1.008 + [.998 - 1.008]x~.8]
. = 1.010 Thus, by replacing Vminr(n) with Vminr(n)* and replacing Vmini(n) with Vmini(n)* in the calcula-tion~ for determining oxygen saturation ratio R we find:
R = ln[Vmaxr(2)/Vminr(2)*]/ln[Vmaxi(2)/Vmini(2)*]
, 20 = ln[1.012/1.00]/ln[1.012/1.00]
', = 1Ø
, Thus, basing the saturation calculations on the corrected minimum transmittance values and the detected maximum transmittance values, the i~, 25 corrected R value corresponds to the same R for the "t~ steady state conditions and the actual oxygen satura-'~ tion of the patient.
,... .
~ x . ~
, x :
,.;: .-, ~;
, ',.~,~
, .....
,, .
. .
. ........ .
"~, , .

,. ....... . .
".
~,..
....

~ ", :; " ~
. ~ . . -: :
.
~,, : :: :~ ' .. :

~ ~ ~33~ 1327402 Circuit Tables REF # CHIP MFR PART # Manufacturer DESCRIPTION OF CHIP
~ 210 U2 LE442 NATIONAL DUAL LOW POWER OP AMP
SEMICONDUCTOR
FIG. 3.

SEMICONDUCTOR
~- 312 U28 LP365N NATIONAL QUAD VOLTAGE COMPARATOR
SEMICONDUCTOR

SEMICONDUCTOR
:~ 320 U27 LF444 NATIONAL QUAD JPET OP AMP
` SEMICONDUCTOR

SEMICONDUCTOR
~: 330 U32 LF444 NATIONAL QUAD JFET OP ANP
: SEMICONDUCTOR

SEMICONDUCTOR
340 U32 LF444 NATIONAL QUAD JFET OP A~P
i SEMICONDUCTOR
' 340 U14 DG243CJ SILICONIX ANALOG SWITCH
INCORPORATED
: 340 U7 LF444 NATIONAL QUAD JFET OP AMP
;-, SEMICONDUCTOR
.. , 340 U13 LF444 NATIONAL QUAD JFET OP AMP
:~ SEMICONDUCTOR

.! SEMICONDUCTOR
~ 360 U13 LF444 NATIONAL QUAD JFET OP AMP
,, SEMICONDUCTOR
~, 370 U7 LF444 NATIONAL QUAD JFET OP AMP
:j 35 SENICONDUCTOR

:~ SEMICONDUCTOR
.i 34~ ~ Ulg DG211CJ SILICONIX CMOS ANALOG SWITCH
;~. . - INCORPORATED
.i 40FI~ 4 ~`. 640 Ul9 DG211CJ SILICONIX CMOS ANALOG SWITCN
~s INCORPORATED
.~. 640 U32 LF444 NATIONAL QUAD JFET OP AMP
SEMICONDUCTOR
. 45 FIG. 5 :, 1010 U24 DG52BCK SILICONIX OCTAL ANALOG SWITCH
~: . INCORPORATED
.~ 1020 U25 LF444 NATIONAL QUAD JFET OP AMP
SEMICONDUCTOR

;~ SEMICONDUCTOR
~ 1040 U38 AD7524LN ANALOG DEVICES DAC

.,, ., : . -.

i :,, ,~ , ::.
. ,,,~
.,"
:,........................................ .

.i ` ~34~ 1327402 INSTRUMENTS

SEMICONDUCTOR
1050 U36 LF3g8N NATIONAL SAMPLE & HOLD OP AMP
SEMICONDUCTOR

. INSTRUMENTS

SEMICONDUCTOR

. SEMICONDUCTOR
:. 610 U18 DG528CK SILICONIX OCTAL ANALOG SWITCH
. 15 INCORPORATED
620 Ull LF444 NATIONAL QUAD JFET OP AMP
:'. SEMICONDUCTOR
.l 630 Ull LF444 NATIONAL QUAD JFET OP ANP
.. ~ SEMICONDUCTOR
~, 20 FIG. 6 .~ U2 82C84A-2 NEC CMOS 8 NHZ CLOCR GENERATOR
.~ Ul 74HC74 TEXAS HIGH SPEED CMOS
:. INSTRUMENTS
Ul 74HC74 TEXAS HIGH SPEED CNOS
- 25 INSTR~MENTS
-~ 2040 U8 MSM80C88RS-2 OKI ELECTRIC CPU 8MHZ, 125ns c U3 74HC74 TEXAS HIGH SPEED CMOS
'~`,! INSTRUMENTS

, 30 INSTRUMENTS
'.~ U9 74HC04 TEXAS HIGH SPEED CMOS
~ INSTRUMENTS
j,'! U3 74HC74 TEXAS HIGH SPEED CMOS
:~ - INSTRUMENTS

INSTRUMENTS
.~ Ul9 74HCOO TEXAS HIGH SPEED CMOS
INSTRUMENTS

~; 40 .~ INSTRUMENTS
2030: U21 MBM27C512-25 FUJITSU LIMITED CMOS 64X X 8 ROM
202~- U15 DS1242 DALLAS CMOS 32K X 8 RAM
~. SEMICONDUCTOR
:~ U23 74HC138 TEXAS HIGH SPEED CMOS
INSTRUMENTS
--i U17 74HC138 TEXAS HIGH SPEED CMOS
'i INSTRUMENTS
``. Ul9 74HCOO TEXAS HIGH SPEED CMOS
INSTRUMENTS
:,~ 50 Ul9 74HCOO TEXAS HIGH SPEED CMOS
INSTRUMENTS

. U22 MSM82C59A-2RS ORI ELECTRIC CMOS INTERRUPT CONTROLLER
~. 2050 U34 MSM82C53-2 OXI EIECTRIC CNOS TRIPLE TIMER
;~; 55 2050 U38 MSM82C53-2 OXI ELECTRIC CMOS TRIPLE TIMER
. ,.
, ...
",: .

. . .
. .
, :, ', ~
.....

-., : . , . ~
: , .. ~ :' , ' ,. " : ' , . :

r INSTRUMENTS

~ CORPORATION
:~ 2050 U40 74HC374 TEXAS HIGH SPEED CNOS
. INSTRUMENTS

INSTRUMENTS

.,, ., . , .
:

, `

., ~ .
i,'' : 'i ., ~ .
: ` .
., ,~

j, .

,,.

.r;: ~.
.

~. f.

:~' .f ~ ~ .
"

, ' . .
~'"' 36- 13274~2 , N z 3 3 3 r ~ ~ W ~ U~ U~ 3 C ccn c .~x x o O x O = O O o O x x x x O x x x N N N N N C
W
~;~ W
X

i 3 Z w 3 ,.3 w ,3 3 ,,~ ~ _ z z ... , ~

.^ Sof tware ,r. Appendix ", , ."~ , . ' '. , .
~ ~r"

f~ ' t, ,~

,.,~' :
: 'i ` ~ ' ' ., '~' . , ~ , 37- ~327402 : .
`:
o o o o o i .. .. ~
:.:, ,, z ~ o o o c Z 4 ~ o 4 :~ Q = c~ s ~ s O f~ x '~ ~x x ~ m w ~
3 X x w X ? X ~a s s x Z--s ., . ~ zl ,~.
''`'f, O O ^ 3 ,~s ` ` ~ _ i ~. Z

, ,.~x ,'.; .
. . ~
~,,.~ , , . .

,. .,~ .

,~
?~
,'"~
. - `
;,.,:~ ` .

", ~ , . . .

.~ ~
--` 13274~2 . .
g .; O O
",, ~
- O ~-,. - .

Z Z ~ C O 0 0 3 0 O ~ 3 N O 3 0 o o o ~ 3 3 o r 0 2 X X X X O X X Y ~ X ~ X X O X X X 2 X o X X X
O ~t Dl a o C~- o cr t~ ~ 1 ~"~ X r~ ~ X X ~ X ~ X X
~ rh 1~ 0 ~ O ~ .
.,." O
; i-,..

C~ X O X ~ 3 t~
"~ O tn r ~ ~ ~o W w C
' ~ I ~ O Z ~3 . Z
x ~; x ~ ~ 3 ~ ~ _ C

", W
-,,. ~ O

.,, .~ .
~ ,~
. ,~j....... . .
"' . .;, .
.. if , ., ..
. ~ :: . . . .
. " ~ . . .
r' : ""

~,."
:.. , . `, ' .
.
~ g 8 o ~ ~ ~ .
.~ ,. .. .
.
.: - ~ ~ ~ ~ Z ~ ~ ~.
.,~ ~ C ~ ~ C~ ~ ~ X

,` X X X X-- X
X X
~ r b ., ~ ..

.
`~
., .
' , , . ~ , , .

.~ . b ~ o ^.~ O-- ~

~ 3.
"1 _ 3 ~' 1 ~ ,~.

: 3 ., . - _ : Z
.~.i _ ., _ .:~

: .
' , ~

., ~
, . . . .. . . ; l , . . . ~ , . .
'' - - ; ' .
.. . .
:'.. ' ., :, ~ ' , ...... . .

Claims (31)

1. A method for detecting and processing arterial pulses of a patient during transient condi-tions by passing a first light frequency through the patient's tissue and detecting a first optical signal corresponding to changes in the transmittance of the first frequency including periodic transmit-tance changes related to the patient's beating heart, aperiodic transmittance changes unrelated to the beating heart, background transmittance, and transient background transmittance changes at frequencies below the heart rate, and passing a second light frequency through the patient's tissue and detecting a second optical signal corresponding to changes in the trans-mittance of the second frequency including periodic transmittance changes related to the patient's beating heart, aperiodic transmittance changes unrelated to the beating heart, background transmittance, and transient background transmittance changes at fre-quencies below the heart rate, characterized by, for each of the first and second detected optical signals:
processing the detected optical signal to detect a first maximum and minimum transmit-tance corresponding to a periodic change related to the heartbeat and a second maximum and minimum transmittance corresponding to a following periodic change related to a following heartbeat;
determining the rate of change in transmittance from one detected transmittance point of one pulse to the corresponding trans-mittance point of the other pulse; and adjusting one of the detected maximum or minimum transmittance values of one of the first or second pulses using the determined rate of change.
2. The method of claim 1 characterized in that for each of the first and second detected optical signals, adjusting the maximum or minimum transmittance by determining the rate of change is further characterized by using linear interpolation based on the maximum and minimum transmittance of one of the first or second pulses and the occurrence of the maximum or minimum of the other pulse.
3. The method of claim 2 characterized in that adjusting one of the maximum or minimum transmittance values of one of the first or second pulses is further characterized by selecting one of the maximum or minimum transmittance values of the first pulse to be adjusted.
4. The method of claim 3 characterized in that adjusting the selected maximum or minimum transmittance value is further characterized by applying the following algorithm:
wherein V(n)* is the adjusted maximum or minimum transmittance; V(n) is the determined maximum or minimum transmittance to be adjusted; tx(n) is the time of occurrence of the detected maximum or mini-mum transmittance to be adjusted; tn(n) is the time of occurrence of the other of the detected maximum or minimum transmittance to be adjusted; and tx(n+1) is the time of occurrence of the second maximum or minimum transmittance that corresponds to the first maximum or minimum transmittance to be adjusted.
5. The method of claim 4 further char-acterized by calculating oxygen saturation of the patient's arterial blood flow using the adjusted first maximum or minimum transmittance and the other of the detected first maximum or minimum transmit-tance for each of the first and second optical signals.
6. The method of claim 2 characterized in that adjusting one of the maximum or minimum transmittance values of one of the first or second pulses is further characterized by selecting one of the maximum or minimum transmittance values of the second pulse to be adjusted.
7. The method of claim 6 characterized in that adjusting the selected maximum or minimum transmittance value is further characterized by applying the following algorithm:
wherein V(n)* is the adjusted maximum or minimum transmittance; V(n) is the determined maximum or minimum transmittance to be adjusted; tx(n) is the time of occurrence of the detected maximum or mini-mum transmittance to be adjusted; tn(n) is the time of occurrence of the other of the detected maximum or minimum transmittance to be adjusted; and tn(n-1) is the time of occurrence of the first maximum or minimum transmittance that corresponds to the second maximum or minimum transmittance to be adjusted.
8. The method of claim 7 further char-acterized by calculating oxygen saturation of the patient's arterial blood flow using the adjusted second maximum or minimum transmittance and the other of the detected second maximum or minimum transmit-tance for each of the first and second optical signals.
9. A method for detecting and processing arterial pulses of a patient during transient conditions comprising:
passing a first light frequency through the patient's tissue and detecting a first optical signal corresponding to changes in the transmittance of the first frequency including periodic transmittance changes related to the patient's beating heart, aperiodic transmittance changes unrelated to the beating heart, background transmittance, and transient background transmittance changes at frequencies below the heart rate;
passing a second light frequency through the patient's tissue and detecting a second optical signal corresponding to changes in the transmittance of a second frequency including periodic transmittance changes related to the patient's beating heart, aperiodic transmittance changes unrelated to the beating heart, background transmittance, and transient background transmittance changes at frequencies below the heart rate; and, for each of the first and second detected optical signals;
processing the first and second detected optical signals to obtain first and second filtered signals substantially comprising the background transmittance and transient background transmittance components of the first and second detected optical signals below the heart rate frequency; and adjusting the first and second detected optical signals by dividing the first and second detected optical signals by the first and second filtered signals, respectively, in phase, thereby providing compensated first and second optical signals.
10. The method of claim 9 further comprising calculating oxygen saturation of the patient's arterial blood flow by processing the compensated first optical signal and the compensated second optical signal to detect the maximum or minimum transmittances in the compensated signals for use in calculating saturation.
11. The method of claim 10 wherein said processing step further comprises passing the first and second optical signals through a low pass filter to remove substantially all of the frequency components above the background transmittance and transient background transmittance frequency components so that the first and second filtered optical signals remain in phase with the first and second detected optical signals.
12. The method of claim 10 wherein said processing step further comprises transforming the first and second detected optical signals into the frequency domain, eliminating frequency spectral components other than low frequencies spectral components below the heart rate of the first and second light frequencies corresponding to the background transmittance and the transient background transmittance changes to provide a filtered low frequency spectrum, and transforming the filtered low frequency spectrum back into the time domain as the filtered signal.
13. Apparatus for compensating distortion in transmittance caused by transient conditions in a patient's plethysmograph waveform having a first and second optical signals corresponding to the trans-mittance of first and second light frequencies passing through the patient's tissue including arterial pul-satile blood flow for use in an oximeter device characterized by:
first means for detecting periodic transmittance changes of the first frequency corre-sponding to the pulsatile blood flow from the first optical signal including a first maximum and minimum transmittance and a second maximum and minimum trans-mittance following the first maximum and minimum;

second means for detecting periodic transmittance changes of the second frequency corre-sponding to pulsatile blood flow from the second optical signal including a first maximum and minimum transmittance and a second maximum and minimum trans-mittance following the first maximum and minimum;
and, for each of the first and second optical signals;
means for determining the rate of change in transmittance from one detected transmittance point of one pulse to the corre-sponding transmittance point of the other pulse;
and processing means for adjusting one of the detected maximum or minimum transmittance values of one of the first or second pulses using the determined rate of change.
14. The apparatus of claim 13 characterized in that the means for determining the rate of change is further characterized by using linear interpolation based on the maximum or minimum transmittance of one of the first or second pulses and the occurrence of the maximum or minimum transmittance value of the other pulse.
15. The apparatus of claim 14 further characterized by first and second digitizing means for digitizing the first and second detected optical signals, and the first and second means for detecting periodic maximums and minimums and the first and second rate determining means and processing means are further characterized by a digital microprocessor.
16. The apparatus of claim 15 characterized in that the means for adjusting one of the detected maximum or minimum transmittance values of one of the first or second pulses is further characterized by means for selecting one of the maximum or minimum transmittance values of the first pulse to be adjusted.
17. The apparatus of claim 16 charac-terized in that the digital microprocessor is further characterized by means for adjusting one of the first maximum or minimum transmittance values by application of the following algorithm:
wherein V(n)* is the adjusted maximum or minimum transmittance; V(n) is the determined maximum or minimum transmittance to be adjusted; tx(n) is the time of occurrence of the detected maximum or minimum transmittance to be adjusted; tn(n) is the time of occurrence of the other of the detected maximum or minimum transmittance to be adjusted; and tx(n+1) is the time of occurrence of the second maximum or minimum transmittance that corresponds to the first maximum or minimum transmittance to be adjusted.
18. The apparatus of claim 17 further characterized by means for calculating oxygen satu-ration using the first and second corrected maximum or minimum transmittances and the other of the detected maximum or minimum transmittances of the first pulses for each of the first and second optical signals.
19. The apparatus of claim 15 charac-terized in that the means for adjusting one of the detected maximum or minimum transmittance values of one of the first or second pulses is further charac-terized by means for selecting one of the maximum or minimum transmittance values of the second pulse to be adjusted.
20. The apparatus of claim 15 charac-terized in that the digital microprocessor is further characterized by means for adjusting one of the first maximum or minimum transmittance values by appli-cation of the following algorithm:
wherein v(n)* is the adjusted maximum or minimum transmittance; v(n) is the determined maximum or minimum transmittance to be adjusted; tx(n) is the time of occurrence of the detected maximum or mini-mum transmittance to be adjusted; tn(n) is the time of occurrence of the other of the detected maximum or minimum transmittance to be adjusted; and tn(n-1) is the time of occurrence of the first maximum or minimum transmittance that corresponds to the second maximum or minimum transmittance to be adjusted.
21. The apparatus of claim 19 further characterized by means for calculating oxygen satu-ration using the first and second corrected maximum or minimum transmittances and the other of the detected maximum or minimum transmittances of the second pulses for each of the first and second optical signals.
22. Apparatus for compensating distortion in transmittance caused by transient conditions in a patient's plethysmograph waveform having periodic changes related to the patient's beating heart, aperiodic changes unrelated to the beating heart, background transmittance, and transient background transmittance changes at frequencies below the heart rate for use in an oximeter device, comprising;
means for receiving a detected optical signal corresponding to the transmittance of a first and second light frequency passing through the patient's tissue;

filter means for eliminating frequency components of the detected optical signal other than those that have a frequency below the frequency of the fundamental heart rate, thereby providing a filtered signal; and dividing means for dividing the detected optical signal by the filtered signal in phase, thereby providing a compensated optical signal.
23. The apparatus of claim 22 further comprising means for calculating oxygen saturation using the compensated optical signal.
24. The apparatus of claim 22 wherein the filter means passes all frequencies below the fundamental heart rate in phase with the detected optical signal.
25. The apparatus of claim 22 wherein the filter means includes:
means for transforming the optical signal into the frequency domain;
spectral filter means for separating the spectral components below the fundamental heart rate into a filtered spectrum; and means for transforming the filtered spectrum back into the time domain, thereby forming the filtered signal.
26. The apparatus of claim 22 wherein the filter means and dividing means include a digital microprocessor device and said apparatus further comprises means for digitizing the detected optical signal into data acceptable for processing by the microprocessor device.
27. Apparatus for compensating distortion in transmittance caused by transient conditions in a patient's plethysmograph waveform having periodic changes related to the patient's beating heart, aperiodic changes unrelated to the beating heart, background transmittance, and transient background transmittance changes at frequencies below the heart rate for use in an oximeter device, comprising:
means for receiving first and second optical signals corresponding to the transmittance of first and second light frequencies passing through the patient's tissue;
first filter means for eliminating the frequency components of the first optical signal other than those that are below the fundamental heart rate, thereby providing a first filtered signal;
second filter means for eliminating the frequency components of the second optical signal other than those that are below the fundamental heart rate, thereby providing a second filtered signal;
a first dividing means for dividing the first optical signal by the first filtered signal in phase, thereby providing a compensated first optical signal; and a second dividing means for dividing the second optical signal by the second filtered signal in phase, thereby providing a compensated second optical signal.
28. The apparatus of claim 27 further comprising means for calculating oxygen saturation using the first compensated optical signal and the second compensated optical signal.
29. The apparatus of claim 27 wherein the first and second filter means pass all frequencies below the fundamental heart rate in phase with the unfiltered signal.
30. The apparatus of claim 27 wherein the first and second filter means include:
first means for transforming the first optical signal into the frequency domain;
first spectral filter means for eliminating the spectral components other than those below the fundamental heart rate into a first filtered spectrum;
means for transforming the filtered spectrum back into the time domain, thereby forming the first filtered signal;
second means for transforming the second optical signal into the frequency domain;
second spectral filter means for eliminating the spectral components other than those below the fundamental heart rate into a second filtered spectrum; and means for transforming the second filtered spectrum back into the time domain, thereby forming the second filtered signal.
31. The apparatus of claim 27 wherein the first and second filter means and dividing means further comprise a digital microprocessor device and said apparatus further comprises means for digitizing the first and second optical signals into data acceptable for processing by the microprocessor device.
CA000595258A 1988-03-30 1989-03-30 Method and apparatus for calculating arterial oxygen saturation based on plethysmographs including transients Expired - Fee Related CA1327402C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US175,115 1988-03-30
US07/175,115 US4869254A (en) 1988-03-30 1988-03-30 Method and apparatus for calculating arterial oxygen saturation

Publications (1)

Publication Number Publication Date
CA1327402C true CA1327402C (en) 1994-03-01

Family

ID=22638970

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000595258A Expired - Fee Related CA1327402C (en) 1988-03-30 1989-03-30 Method and apparatus for calculating arterial oxygen saturation based on plethysmographs including transients

Country Status (7)

Country Link
US (1) US4869254A (en)
EP (1) EP0335356B1 (en)
JP (1) JP2602321B2 (en)
AT (1) ATE135547T1 (en)
CA (1) CA1327402C (en)
DE (1) DE68925988T2 (en)
FI (1) FI891493A (en)

Families Citing this family (225)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5873821A (en) * 1992-05-18 1999-02-23 Non-Invasive Technology, Inc. Lateralization spectrophotometer
JPH02164341A (en) * 1988-12-19 1990-06-25 Nippon Koden Corp Hemoglobin concentration measuring device
US5353799A (en) 1991-01-22 1994-10-11 Non Invasive Technology, Inc. Examination of subjects using photon migration with high directionality techniques
US5782755A (en) * 1993-11-15 1998-07-21 Non-Invasive Technology, Inc. Monitoring one or more solutes in a biological system using optical techniques
US5040539A (en) * 1989-05-12 1991-08-20 The United States Of America Pulse oximeter for diagnosis of dental pulp pathology
US5299120A (en) * 1989-09-15 1994-03-29 Hewlett-Packard Company Method for digitally processing signals containing information regarding arterial blood flow
US5094239A (en) * 1989-10-05 1992-03-10 Colin Electronics Co., Ltd. Composite signal implementation for acquiring oximetry signals
US5190038A (en) * 1989-11-01 1993-03-02 Novametrix Medical Systems, Inc. Pulse oximeter with improved accuracy and response time
US5845639A (en) * 1990-08-10 1998-12-08 Board Of Regents Of The University Of Washington Optical imaging methods
JP3021628B2 (en) * 1990-11-27 2000-03-15 興和株式会社 Blood flow measurement device
ATE184716T1 (en) * 1991-03-07 1999-10-15 Masimo Corp DEVICE AND METHOD FOR SIGNAL PROCESSING
US5490505A (en) * 1991-03-07 1996-02-13 Masimo Corporation Signal processing apparatus
MX9702434A (en) * 1991-03-07 1998-05-31 Masimo Corp Signal processing apparatus.
US5632272A (en) 1991-03-07 1997-05-27 Masimo Corporation Signal processing apparatus
US5226417A (en) * 1991-03-11 1993-07-13 Nellcor, Inc. Apparatus for the detection of motion transients
US6549795B1 (en) 1991-05-16 2003-04-15 Non-Invasive Technology, Inc. Spectrophotometer for tissue examination
US6987994B1 (en) 1991-09-03 2006-01-17 Datex-Ohmeda, Inc. Pulse oximetry SpO2 determination
US6714803B1 (en) 1991-09-03 2004-03-30 Datex-Ohmeda, Inc. Pulse oximetry SpO2 determination
US5934277A (en) 1991-09-03 1999-08-10 Datex-Ohmeda, Inc. System for pulse oximetry SpO2 determination
US5246002A (en) * 1992-02-11 1993-09-21 Physio-Control Corporation Noise insensitive pulse transmittance oximeter
US6785568B2 (en) * 1992-05-18 2004-08-31 Non-Invasive Technology Inc. Transcranial examination of the brain
US5954053A (en) * 1995-06-06 1999-09-21 Non-Invasive Technology, Inc. Detection of brain hematoma
US5368224A (en) * 1992-10-23 1994-11-29 Nellcor Incorporated Method for reducing ambient noise effects in electronic monitoring instruments
US5372134A (en) * 1993-05-24 1994-12-13 Richardson; Joseph W. Aviation hypoxia monitor
US6058324A (en) * 1993-06-17 2000-05-02 Non-Invasive Technology, Inc. Examination and imaging of biological tissue
US5820558A (en) * 1994-12-02 1998-10-13 Non-Invasive Technology, Inc. Optical techniques for examination of biological tissue
US5673701A (en) * 1994-10-07 1997-10-07 Non Invasive Technology, Inc. Optical techniques for examination of biological tissue
US7376453B1 (en) 1993-10-06 2008-05-20 Masimo Corporation Signal processing apparatus
US6493565B1 (en) 1993-11-15 2002-12-10 Non-Invasive Technology, Inc. Examination of biological tissue by monitoring one or more solutes
US5560355A (en) * 1993-12-17 1996-10-01 Nellcor Puritan Bennett Incorporated Medical sensor with amplitude independent output
US5553615A (en) * 1994-01-31 1996-09-10 Minnesota Mining And Manufacturing Company Method and apparatus for noninvasive prediction of hematocrit
EP0752143B2 (en) * 1994-03-24 2005-07-20 Minnesota Mining And Manufacturing Company Biometric, personal authentication system
US5575284A (en) * 1994-04-01 1996-11-19 University Of South Florida Portable pulse oximeter
EP1905352B1 (en) 1994-10-07 2014-07-16 Masimo Corporation Signal processing method
US8019400B2 (en) 1994-10-07 2011-09-13 Masimo Corporation Signal processing apparatus
US5503148A (en) * 1994-11-01 1996-04-02 Ohmeda Inc. System for pulse oximetry SPO2 determination
US5505199A (en) * 1994-12-01 1996-04-09 Kim; Bill H. Sudden infant death syndrome monitor
US6957094B2 (en) * 1994-12-02 2005-10-18 Non-Invasive Technology, Inc. Examination of scattering properties of biological tissue
US6542772B1 (en) * 1994-12-02 2003-04-01 Non-Invasive Technology, Inc. Examination and imaging of biological tissue
US5853364A (en) * 1995-08-07 1998-12-29 Nellcor Puritan Bennett, Inc. Method and apparatus for estimating physiological parameters using model-based adaptive filtering
AUPN740796A0 (en) * 1996-01-04 1996-01-25 Circuitry Systems Limited Biomedical data collection apparatus
US5978691A (en) * 1996-07-19 1999-11-02 Mills; Alexander Knight Device and method for noninvasive continuous determination of blood gases, pH, hemoglobin level, and oxygen content
JP3925945B2 (en) * 1996-07-26 2007-06-06 ラディオメーター・バーゼル・アクチェンゲゼルシャフト A method for measuring oxygen saturation in tissues that are supplied with blood without damaging the specimen
US6018673A (en) 1996-10-10 2000-01-25 Nellcor Puritan Bennett Incorporated Motion compatible sensor for non-invasive optical blood analysis
US5800349A (en) * 1996-10-15 1998-09-01 Nonin Medical, Inc. Offset pulse oximeter sensor
US5830137A (en) * 1996-11-18 1998-11-03 University Of South Florida Green light pulse oximeter
US5921921A (en) * 1996-12-18 1999-07-13 Nellcor Puritan-Bennett Pulse oximeter with sigma-delta converter
US5935076A (en) * 1997-02-10 1999-08-10 University Of Alabama In Huntsville Method and apparatus for accurately measuring the transmittance of blood within a retinal vessel
US5776060A (en) * 1997-02-20 1998-07-07 University Of Alabama In Huntsville Method and apparatus for measuring blood oxygen saturation within a retinal vessel with light having several selected wavelengths
US6002952A (en) 1997-04-14 1999-12-14 Masimo Corporation Signal processing apparatus and method
US6343223B1 (en) * 1997-07-30 2002-01-29 Mallinckrodt Inc. Oximeter sensor with offset emitters and detector and heating device
US6115621A (en) * 1997-07-30 2000-09-05 Nellcor Puritan Bennett Incorporated Oximetry sensor with offset emitters and detector
US6400973B1 (en) 1998-01-20 2002-06-04 Bowden's Automated Products, Inc. Arterial blood flow simulator
US6694157B1 (en) 1998-02-10 2004-02-17 Daedalus I , L.L.C. Method and apparatus for determination of pH pCO2, hemoglobin, and hemoglobin oxygen saturation
WO1999040841A1 (en) * 1998-02-11 1999-08-19 Non-Invasive Technology, Inc. Imaging and characterization of brain tissue
WO1999040840A1 (en) * 1998-02-11 1999-08-19 Non-Invasive Technology, Inc. Detection, imaging and characterization of breast tumors
DE69941975D1 (en) * 1998-02-13 2010-03-18 Non Invasive Technology Inc INVESTIGATION, OBSERVATION AND IMAGE DISPLAY OF ABDOMINAL TISSUE
US20070167704A1 (en) * 1998-02-13 2007-07-19 Britton Chance Transabdominal examination, monitoring and imaging of tissue
US6094592A (en) * 1998-05-26 2000-07-25 Nellcor Puritan Bennett, Inc. Methods and apparatus for estimating a physiological parameter using transforms
US6144444A (en) * 1998-11-06 2000-11-07 Medtronic Avecor Cardiovascular, Inc. Apparatus and method to determine blood parameters
US6675031B1 (en) 1999-04-14 2004-01-06 Mallinckrodt Inc. Method and circuit for indicating quality and accuracy of physiological measurements
US7840257B2 (en) * 2003-01-04 2010-11-23 Non Invasive Technology, Inc. Examination of biological tissue using non-contact optical probes
US7904139B2 (en) 1999-08-26 2011-03-08 Non-Invasive Technology Inc. Optical examination of biological tissue using non-contact irradiation and detection
US7177686B1 (en) 1999-11-10 2007-02-13 Pacesetter, Inc. Using photo-plethysmography to monitor autonomic tone and performing pacing optimization based on monitored autonomic tone
US6408198B1 (en) 1999-12-17 2002-06-18 Datex-Ohmeda, Inc. Method and system for improving photoplethysmographic analyte measurements by de-weighting motion-contaminated data
US8224412B2 (en) 2000-04-17 2012-07-17 Nellcor Puritan Bennett Llc Pulse oximeter sensor with piece-wise function
EP2322085B1 (en) 2000-04-17 2014-03-12 Covidien LP Pulse oximeter sensor with piece-wise function
US6510331B1 (en) * 2000-06-05 2003-01-21 Glenn Williams Switching device for multi-sensor array
US6434408B1 (en) * 2000-09-29 2002-08-13 Datex-Ohmeda, Inc. Pulse oximetry method and system with improved motion correction
US6748254B2 (en) 2001-10-12 2004-06-08 Nellcor Puritan Bennett Incorporated Stacked adhesive optical sensor
US6896661B2 (en) * 2002-02-22 2005-05-24 Datex-Ohmeda, Inc. Monitoring physiological parameters based on variations in a photoplethysmographic baseline signal
WO2003071938A1 (en) * 2002-02-22 2003-09-04 Datex-Ohmeda, Inc. Monitoring physiological parameters based on variations in a photoplethysmographic signal
US6702752B2 (en) 2002-02-22 2004-03-09 Datex-Ohmeda, Inc. Monitoring respiration based on plethysmographic heart rate signal
US6805673B2 (en) 2002-02-22 2004-10-19 Datex-Ohmeda, Inc. Monitoring mayer wave effects based on a photoplethysmographic signal
US6709402B2 (en) 2002-02-22 2004-03-23 Datex-Ohmeda, Inc. Apparatus and method for monitoring respiration with a pulse oximeter
CN1723480A (en) * 2002-05-13 2006-01-18 斯科特实验室公司 System and method for transparent early detection, warning, and intervention during a medical procedure
WO2004019780A1 (en) * 2002-08-28 2004-03-11 Akiyasu Fukumura In-vivo oxygen saturation degree determining method and instrument using near infrared radiation, and sensor sensitivity reference calibrator used for the instrument
US7190986B1 (en) 2002-10-18 2007-03-13 Nellcor Puritan Bennett Inc. Non-adhesive oximeter sensor for sensitive skin
KR100552681B1 (en) 2003-04-25 2006-02-20 삼성전자주식회사 Apparatus and method for diagnosing sleep apnea
DE10333101B4 (en) * 2003-07-21 2008-05-21 Qimonda Ag Calibration means for calibrating a tester channel of a tester, tester system and method for calibrating a tester channel
GB2413078C (en) 2004-01-08 2012-08-15 Dialog Devices Ltd A system or method for assessing a subject's pedalblood circulation.
US7162288B2 (en) 2004-02-25 2007-01-09 Nellcor Purtain Bennett Incorporated Techniques for detecting heart pulses and reducing power consumption in sensors
US7194293B2 (en) * 2004-03-08 2007-03-20 Nellcor Puritan Bennett Incorporated Selection of ensemble averaging weights for a pulse oximeter based on signal quality metrics
US7909768B1 (en) * 2004-07-19 2011-03-22 Pacesetter, Inc. Reducing data acquisition, power and processing for hemodynamic signal sampling
US7324848B1 (en) 2004-07-19 2008-01-29 Pacesetter, Inc. Reducing data acquisition, power and processing for photoplethysmography and other applications
US7690378B1 (en) * 2004-07-21 2010-04-06 Pacesetter, Inc. Methods, systems and devices for monitoring respiratory disorders
US7623990B2 (en) * 2004-11-03 2009-11-24 Draeger Medical Systems, Inc. System for reducing signal interference in modulated signal communication
US8116839B1 (en) 2005-02-25 2012-02-14 General Electric Company System for detecting potential probe malfunction conditions in a pulse oximeter
US7761127B2 (en) 2005-03-01 2010-07-20 Masimo Laboratories, Inc. Multiple wavelength sensor substrate
US8055321B2 (en) 2005-03-14 2011-11-08 Peter Bernreuter Tissue oximetry apparatus and method
US7865223B1 (en) * 2005-03-14 2011-01-04 Peter Bernreuter In vivo blood spectrometry
US7403806B2 (en) 2005-06-28 2008-07-22 General Electric Company System for prefiltering a plethysmographic signal
US7657294B2 (en) 2005-08-08 2010-02-02 Nellcor Puritan Bennett Llc Compliant diaphragm medical sensor and technique for using the same
US7590439B2 (en) 2005-08-08 2009-09-15 Nellcor Puritan Bennett Llc Bi-stable medical sensor and technique for using the same
US7657295B2 (en) 2005-08-08 2010-02-02 Nellcor Puritan Bennett Llc Medical sensor and technique for using the same
US20070060808A1 (en) 2005-09-12 2007-03-15 Carine Hoarau Medical sensor for reducing motion artifacts and technique for using the same
US7904130B2 (en) 2005-09-29 2011-03-08 Nellcor Puritan Bennett Llc Medical sensor and technique for using the same
US8092379B2 (en) 2005-09-29 2012-01-10 Nellcor Puritan Bennett Llc Method and system for determining when to reposition a physiological sensor
US7899510B2 (en) 2005-09-29 2011-03-01 Nellcor Puritan Bennett Llc Medical sensor and technique for using the same
US7869850B2 (en) 2005-09-29 2011-01-11 Nellcor Puritan Bennett Llc Medical sensor for reducing motion artifacts and technique for using the same
US7881762B2 (en) 2005-09-30 2011-02-01 Nellcor Puritan Bennett Llc Clip-style medical sensor and technique for using the same
US7555327B2 (en) 2005-09-30 2009-06-30 Nellcor Puritan Bennett Llc Folding medical sensor and technique for using the same
US8233954B2 (en) 2005-09-30 2012-07-31 Nellcor Puritan Bennett Llc Mucosal sensor for the assessment of tissue and blood constituents and technique for using the same
US8062221B2 (en) 2005-09-30 2011-11-22 Nellcor Puritan Bennett Llc Sensor for tissue gas detection and technique for using the same
US7483731B2 (en) 2005-09-30 2009-01-27 Nellcor Puritan Bennett Llc Medical sensor and technique for using the same
US7486979B2 (en) 2005-09-30 2009-02-03 Nellcor Puritan Bennett Llc Optically aligned pulse oximetry sensor and technique for using the same
US7328114B2 (en) * 2005-12-09 2008-02-05 General Electric Company Methods and systems for measuring a rate of change of frequency
US7522948B2 (en) 2006-05-02 2009-04-21 Nellcor Puritan Bennett Llc Medical sensor and technique for using the same
US8073518B2 (en) 2006-05-02 2011-12-06 Nellcor Puritan Bennett Llc Clip-style medical sensor and technique for using the same
US7477924B2 (en) 2006-05-02 2009-01-13 Nellcor Puritan Bennett Llc Medical sensor and technique for using the same
CA2657471A1 (en) * 2006-07-12 2008-01-24 Intertechnique A respiratory gas supply circuit to feed crew members and passengers of an aircraft with oxygen
US8145288B2 (en) 2006-08-22 2012-03-27 Nellcor Puritan Bennett Llc Medical sensor for reducing signal artifacts and technique for using the same
US8219170B2 (en) 2006-09-20 2012-07-10 Nellcor Puritan Bennett Llc System and method for practicing spectrophotometry using light emitting nanostructure devices
US8175671B2 (en) 2006-09-22 2012-05-08 Nellcor Puritan Bennett Llc Medical sensor for reducing signal artifacts and technique for using the same
US8195264B2 (en) 2006-09-22 2012-06-05 Nellcor Puritan Bennett Llc Medical sensor for reducing signal artifacts and technique for using the same
US8396527B2 (en) 2006-09-22 2013-03-12 Covidien Lp Medical sensor for reducing signal artifacts and technique for using the same
US7869849B2 (en) 2006-09-26 2011-01-11 Nellcor Puritan Bennett Llc Opaque, electrically nonconductive region on a medical sensor
US7574245B2 (en) 2006-09-27 2009-08-11 Nellcor Puritan Bennett Llc Flexible medical sensor enclosure
US7796403B2 (en) 2006-09-28 2010-09-14 Nellcor Puritan Bennett Llc Means for mechanical registration and mechanical-electrical coupling of a faraday shield to a photodetector and an electrical circuit
US7890153B2 (en) 2006-09-28 2011-02-15 Nellcor Puritan Bennett Llc System and method for mitigating interference in pulse oximetry
US8175667B2 (en) 2006-09-29 2012-05-08 Nellcor Puritan Bennett Llc Symmetric LED array for pulse oximetry
US7698002B2 (en) * 2006-09-29 2010-04-13 Nellcor Puritan Bennett Llc Systems and methods for user interface and identification in a medical device
US7925511B2 (en) 2006-09-29 2011-04-12 Nellcor Puritan Bennett Llc System and method for secure voice identification in a medical device
US7476131B2 (en) 2006-09-29 2009-01-13 Nellcor Puritan Bennett Llc Device for reducing crosstalk
US7706896B2 (en) 2006-09-29 2010-04-27 Nellcor Puritan Bennett Llc User interface and identification in a medical device system and method
US7680522B2 (en) 2006-09-29 2010-03-16 Nellcor Puritan Bennett Llc Method and apparatus for detecting misapplied sensors
US8068891B2 (en) 2006-09-29 2011-11-29 Nellcor Puritan Bennett Llc Symmetric LED array for pulse oximetry
US20080097175A1 (en) * 2006-09-29 2008-04-24 Boyce Robin S System and method for display control of patient monitor
US7684842B2 (en) 2006-09-29 2010-03-23 Nellcor Puritan Bennett Llc System and method for preventing sensor misuse
US20080081956A1 (en) 2006-09-29 2008-04-03 Jayesh Shah System and method for integrating voice with a medical device
FR2907940B1 (en) 2006-10-25 2009-05-01 Sagem Defense Securite METHOD FOR VALIDATION OF BODY FOOTPRINT CAPTURE, IN PARTICULAR A DIGITAL IMPRINT
US8092386B1 (en) 2006-12-22 2012-01-10 Pacesetter, Inc. Method and implantable system for blood-glucose concentration monitoring
US7894869B2 (en) 2007-03-09 2011-02-22 Nellcor Puritan Bennett Llc Multiple configuration medical sensor and technique for using the same
US8265724B2 (en) 2007-03-09 2012-09-11 Nellcor Puritan Bennett Llc Cancellation of light shunting
US8280469B2 (en) 2007-03-09 2012-10-02 Nellcor Puritan Bennett Llc Method for detection of aberrant tissue spectra
EP2139383B1 (en) 2007-03-27 2013-02-13 Masimo Laboratories, Inc. Multiple wavelength optical sensor
US8374665B2 (en) 2007-04-21 2013-02-12 Cercacor Laboratories, Inc. Tissue profile wellness monitor
US8369944B2 (en) 2007-06-06 2013-02-05 Zoll Medical Corporation Wearable defibrillator with audio input/output
US8271082B2 (en) 2007-06-07 2012-09-18 Zoll Medical Corporation Medical device configured to test for user responsiveness
US20080306470A1 (en) * 2007-06-11 2008-12-11 Joshua Friedman Optical screening device
US20080306361A1 (en) * 2007-06-11 2008-12-11 Joshua Friedman Optical screening device
US7974689B2 (en) 2007-06-13 2011-07-05 Zoll Medical Corporation Wearable medical treatment device with motion/position detection
US8140154B2 (en) 2007-06-13 2012-03-20 Zoll Medical Corporation Wearable medical treatment device
US7920913B1 (en) 2007-06-29 2011-04-05 Pacesetter, Inc. Systems and methods for increasing implantable sensor accuracy
CN101347334B (en) * 2007-07-19 2012-09-05 深圳迈瑞生物医疗电子股份有限公司 Method and device for measuring blood oxygen saturation
US8517941B1 (en) 2007-10-23 2013-08-27 Pacesetter, Inc. Implantable cardiac device and method for monitoring blood-glucose concentration
US8352004B2 (en) 2007-12-21 2013-01-08 Covidien Lp Medical sensor and technique for using the same
US8346328B2 (en) 2007-12-21 2013-01-01 Covidien Lp Medical sensor and technique for using the same
US8366613B2 (en) 2007-12-26 2013-02-05 Covidien Lp LED drive circuit for pulse oximetry and method for using same
US8577434B2 (en) 2007-12-27 2013-11-05 Covidien Lp Coaxial LED light sources
US8442608B2 (en) 2007-12-28 2013-05-14 Covidien Lp System and method for estimating physiological parameters by deconvolving artifacts
US8452364B2 (en) 2007-12-28 2013-05-28 Covidien LLP System and method for attaching a sensor to a patient's skin
US8897850B2 (en) 2007-12-31 2014-11-25 Covidien Lp Sensor with integrated living hinge and spring
US8092993B2 (en) 2007-12-31 2012-01-10 Nellcor Puritan Bennett Llc Hydrogel thin film for use as a biosensor
US8070508B2 (en) 2007-12-31 2011-12-06 Nellcor Puritan Bennett Llc Method and apparatus for aligning and securing a cable strain relief
US8199007B2 (en) 2007-12-31 2012-06-12 Nellcor Puritan Bennett Llc Flex circuit snap track for a biometric sensor
US8437822B2 (en) 2008-03-28 2013-05-07 Covidien Lp System and method for estimating blood analyte concentration
US8112375B2 (en) 2008-03-31 2012-02-07 Nellcor Puritan Bennett Llc Wavelength selection and outlier detection in reduced rank linear models
US7880884B2 (en) 2008-06-30 2011-02-01 Nellcor Puritan Bennett Llc System and method for coating and shielding electronic sensor components
US7887345B2 (en) 2008-06-30 2011-02-15 Nellcor Puritan Bennett Llc Single use connector for pulse oximetry sensors
US8071935B2 (en) 2008-06-30 2011-12-06 Nellcor Puritan Bennett Llc Optical detector with an overmolded faraday shield
US8364220B2 (en) 2008-09-25 2013-01-29 Covidien Lp Medical sensor and technique for using the same
US8914088B2 (en) 2008-09-30 2014-12-16 Covidien Lp Medical sensor and technique for using the same
US8417309B2 (en) 2008-09-30 2013-04-09 Covidien Lp Medical sensor
US8423112B2 (en) 2008-09-30 2013-04-16 Covidien Lp Medical sensor and technique for using the same
US8725226B2 (en) 2008-11-14 2014-05-13 Nonin Medical, Inc. Optical sensor path selection
US8452366B2 (en) 2009-03-16 2013-05-28 Covidien Lp Medical monitoring device with flexible circuitry
US8221319B2 (en) 2009-03-25 2012-07-17 Nellcor Puritan Bennett Llc Medical device for assessing intravascular blood volume and technique for using the same
US8630692B2 (en) * 2009-04-30 2014-01-14 Pacesetter, Inc. Method and implantable system for blood-glucose concentration monitoring using parallel methodologies
JP4571220B2 (en) * 2009-05-13 2010-10-27 ネルコー ピューリタン ベネット エルエルシー Data signal adaptive averaging method and apparatus
US8509869B2 (en) 2009-05-15 2013-08-13 Covidien Lp Method and apparatus for detecting and analyzing variations in a physiologic parameter
US8634891B2 (en) 2009-05-20 2014-01-21 Covidien Lp Method and system for self regulation of sensor component contact pressure
US9010634B2 (en) 2009-06-30 2015-04-21 Covidien Lp System and method for linking patient data to a patient and providing sensor quality assurance
US8311601B2 (en) 2009-06-30 2012-11-13 Nellcor Puritan Bennett Llc Reflectance and/or transmissive pulse oximeter
US8505821B2 (en) 2009-06-30 2013-08-13 Covidien Lp System and method for providing sensor quality assurance
US8290730B2 (en) 2009-06-30 2012-10-16 Nellcor Puritan Bennett Ireland Systems and methods for assessing measurements in physiological monitoring devices
US8636667B2 (en) 2009-07-06 2014-01-28 Nellcor Puritan Bennett Ireland Systems and methods for processing physiological signals in wavelet space
US8391941B2 (en) 2009-07-17 2013-03-05 Covidien Lp System and method for memory switching for multiple configuration medical sensor
US8417310B2 (en) 2009-08-10 2013-04-09 Covidien Lp Digital switching in multi-site sensor
US8428675B2 (en) 2009-08-19 2013-04-23 Covidien Lp Nanofiber adhesives used in medical devices
US8076925B2 (en) * 2009-10-28 2011-12-13 Optisense Network, Inc. Optical sensor assembly for installation on a current carrying cable
US8395372B2 (en) * 2009-10-28 2013-03-12 Optisense Network, Llc Method for measuring current in an electric power distribution system
US9134344B2 (en) 2009-10-28 2015-09-15 Gridview Optical Solutions, Llc. Optical sensor assembly for installation on a current carrying cable
US9839381B1 (en) 2009-11-24 2017-12-12 Cercacor Laboratories, Inc. Physiological measurement system with automatic wavelength adjustment
DE112010004682T5 (en) 2009-12-04 2013-03-28 Masimo Corporation Calibration for multi-level physiological monitors
CN103025379B (en) 2010-05-18 2016-02-17 佐尔医药公司 Wearable therapeutic device
EP2571419B1 (en) 2010-05-18 2020-02-12 Zoll Medical Corporation Wearable ambulatory medical device with multiple sensing electrodes
US8521246B2 (en) 2010-07-29 2013-08-27 Covidien Lp Cable cross talk suppression
US9937355B2 (en) 2010-11-08 2018-04-10 Zoll Medical Corporation Remote medical device alarm
EP2648609B1 (en) 2010-12-09 2018-05-30 Zoll Medical Corporation Electrode with redundant impedance reduction
US9007216B2 (en) 2010-12-10 2015-04-14 Zoll Medical Corporation Wearable therapeutic device
US9427564B2 (en) 2010-12-16 2016-08-30 Zoll Medical Corporation Water resistant wearable medical device
US8761853B2 (en) 2011-01-20 2014-06-24 Nitto Denko Corporation Devices and methods for non-invasive optical physiological measurements
JP6166253B2 (en) 2011-03-25 2017-07-19 ゾール メディカル コーポレイションZOLL Medical Corporation Controller and method for adapting alarms in wearable medical devices
US9684767B2 (en) 2011-03-25 2017-06-20 Zoll Medical Corporation System and method for adapting alarms in a wearable medical device
US8600486B2 (en) 2011-03-25 2013-12-03 Zoll Medical Corporation Method of detecting signal clipping in a wearable ambulatory medical device
US8897860B2 (en) 2011-03-25 2014-11-25 Zoll Medical Corporation Selection of optimal channel for rate determination
EP2704625A4 (en) 2011-05-02 2014-10-01 Zoll Medical Corp Patient-worn energy delivery apparatus and techniques for sizing same
CN105661695A (en) 2011-09-01 2016-06-15 佐尔医药公司 Wearable monitoring and treatment device
CN102512178B (en) * 2011-12-23 2014-04-09 深圳市理邦精密仪器股份有限公司 Blood oxygen measurer and method
US11097107B2 (en) 2012-05-31 2021-08-24 Zoll Medical Corporation External pacing device with discomfort management
WO2013181617A2 (en) 2012-05-31 2013-12-05 Zoll Medical Corporation Medical monitoring and treatment device with external pacing
US10328266B2 (en) 2012-05-31 2019-06-25 Zoll Medical Corporation External pacing device with discomfort management
US9535097B2 (en) 2012-07-19 2017-01-03 Gridview Optical Solutions, Llc. Electro-optic current sensor with high dynamic range and accuracy
US10244949B2 (en) 2012-10-07 2019-04-02 Rhythm Diagnostic Systems, Inc. Health monitoring systems and methods
USD850626S1 (en) 2013-03-15 2019-06-04 Rhythm Diagnostic Systems, Inc. Health monitoring apparatuses
US10413251B2 (en) 2012-10-07 2019-09-17 Rhythm Diagnostic Systems, Inc. Wearable cardiac monitor
US10610159B2 (en) 2012-10-07 2020-04-07 Rhythm Diagnostic Systems, Inc. Health monitoring systems and methods
US9999393B2 (en) 2013-01-29 2018-06-19 Zoll Medical Corporation Delivery of electrode gel using CPR puck
US8880196B2 (en) 2013-03-04 2014-11-04 Zoll Medical Corporation Flexible therapy electrode
US9146358B2 (en) 2013-07-16 2015-09-29 Gridview Optical Solutions, Llc Collimator holder for electro-optical sensor
US9597523B2 (en) 2014-02-12 2017-03-21 Zoll Medical Corporation System and method for adapting alarms in a wearable medical device
WO2016100906A1 (en) 2014-12-18 2016-06-23 Zoll Medical Corporation Pacing device with acoustic sensor
US10321877B2 (en) 2015-03-18 2019-06-18 Zoll Medical Corporation Medical device with acoustic sensor
CA2983771A1 (en) * 2015-06-26 2016-12-29 Rhythm Diagnostic Systems, Inc. Health monitoring systems and methods
WO2017091502A1 (en) 2015-11-23 2017-06-01 Zoll Medical Corporation Garments for wearable medical devices
US11617538B2 (en) 2016-03-14 2023-04-04 Zoll Medical Corporation Proximity based processing systems and methods
EP3838139B1 (en) 2016-12-05 2024-01-03 Medipines Corporation Device for respiratory measurements using breathing gas samples
US11009870B2 (en) 2017-06-06 2021-05-18 Zoll Medical Corporation Vehicle compatible ambulatory defibrillator
US10646707B2 (en) 2017-11-30 2020-05-12 Zoll Medical Corporation Medical devices with rapid sensor recovery
US11568984B2 (en) 2018-09-28 2023-01-31 Zoll Medical Corporation Systems and methods for device inventory management and tracking
WO2020069308A1 (en) 2018-09-28 2020-04-02 Zoll Medical Corporation Adhesively coupled wearable medical device
WO2020139880A1 (en) 2018-12-28 2020-07-02 Zoll Medical Corporation Wearable medical device response mechanisms and methods of use
JP2022546991A (en) 2019-08-28 2022-11-10 アールディーエス Vital signs or health monitoring system and method
CN213609416U (en) 2019-10-09 2021-07-06 Zoll医疗公司 Treatment electrode part and wearable treatment device

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3412729A (en) * 1965-08-30 1968-11-26 Nasa Usa Method and apparatus for continuously monitoring blood oxygenation, blood pressure, pulse rate and the pressure pulse curve utilizing an ear oximeter as transducer
US3704706A (en) * 1969-10-23 1972-12-05 Univ Drexel Heart rate and respiratory monitor
JPS5725217B2 (en) * 1974-10-14 1982-05-28
CA1037285A (en) * 1975-04-30 1978-08-29 Glenfield Warner Ear oximetry process and apparatus
US3994284A (en) * 1975-12-31 1976-11-30 Systron Donner Corporation Flow rate computer adjunct for use with an impedance plethysmograph and method
JPS5493890A (en) * 1977-12-30 1979-07-25 Minolta Camera Kk Eyeeground oximeter
JPS5524004A (en) * 1978-06-22 1980-02-20 Minolta Camera Kk Oxymeter
FR2461482A1 (en) * 1979-07-24 1981-02-06 Balique Georges APPARATUS FOR RECORDING, MONITORING AND SCREENING CARDIOVASCULAR DISORDERS
US4407290A (en) * 1981-04-01 1983-10-04 Biox Technology, Inc. Blood constituent measuring device and method
JPS58143243A (en) * 1982-02-19 1983-08-25 Minolta Camera Co Ltd Measuring apparatus for coloring matter in blood without taking out blood
DE3381580D1 (en) * 1982-09-02 1990-06-28 Nellcor Inc DISPLAY DEVICE FOR PULSES AND OXYGEN CONTENT.
DE3382674T2 (en) * 1982-09-02 1993-07-08 Nellcor Inc OXYGEN MEASURING DEVICE WITH OXYGEN MEASURING PROBE.
EP0102816A3 (en) * 1982-09-02 1985-08-28 Nellcor Incorporated Pulse oximeter
US4802486A (en) * 1985-04-01 1989-02-07 Nellcor Incorporated Method and apparatus for detecting optical pulses
US4651741A (en) * 1985-05-30 1987-03-24 Baxter Travenol Laboratories, Inc. Method and apparatus for determining oxygen saturation in vivo
JPS62109547A (en) * 1985-08-30 1987-05-20 クリテイケア システムズ インコ−ポレ−テツド Oxymetry method and apparatus
US4759369A (en) * 1986-07-07 1988-07-26 Novametrix Medical Systems, Inc. Pulse oximeter
US4869253A (en) * 1986-08-18 1989-09-26 Physio-Control Corporation Method and apparatus for indicating perfusion and oxygen saturation trends in oximetry

Also Published As

Publication number Publication date
DE68925988D1 (en) 1996-04-25
JP2602321B2 (en) 1997-04-23
JPH02203843A (en) 1990-08-13
FI891493A (en) 1989-10-01
EP0335356A2 (en) 1989-10-04
EP0335356B1 (en) 1996-03-20
EP0335356A3 (en) 1990-08-29
ATE135547T1 (en) 1996-04-15
FI891493A0 (en) 1989-03-29
DE68925988T2 (en) 1996-11-07
US4869254A (en) 1989-09-26

Similar Documents

Publication Publication Date Title
CA1327402C (en) Method and apparatus for calculating arterial oxygen saturation based on plethysmographs including transients
US5078136A (en) Method and apparatus for calculating arterial oxygen saturation based plethysmographs including transients
EP0335357B1 (en) Improved method and apparatus for detecting optical pulses
CA2260928C (en) Direct to digital oximeter
US5193543A (en) Method and apparatus for measuring arterial blood constituents
US6360113B1 (en) Photoplethysmographic instrument
US4863265A (en) Apparatus and method for measuring blood constituents
US7184809B1 (en) Pulse amplitude indexing method and apparatus
US6163715A (en) Direct to digital oximeter and method for calculating oxygenation levels
US6178343B1 (en) Pulse rate and heart rate coincidence detection for pulse oximetry
US4819752A (en) Blood constituent measuring device and method
US20070106136A1 (en) Method and apparatus for processing signals reflecting physiological characteristics
EP0261788B1 (en) Multiple-pulse method and apparatus for use in oximetry
US5800348A (en) Apparatus and method for medical monitoring, in particular pulse oximeter
US5860919A (en) Active pulse blood constituent monitoring method
US20050272987A1 (en) Active pulse blood constituent monitoring
AU605552B2 (en) Oximeter apparatus and method for measuring arterial blood constituents
WO1982003322A1 (en) Blood constituent measuring device and method
WO2008039195A1 (en) Pulse amplitude indexing method and apparatus
CN107427240B (en) Optical analysis system and method
EP2073695A1 (en) Method and apparatus for processing signals reflecting physiological characteristics
RU2152030C1 (en) Pulsating oximeter
AU770773B2 (en) Direct to digital oximeter and method for calculating oxygenation levels
Wankhar DEVELOPMENT OF A PULSE OXIMETER

Legal Events

Date Code Title Description
MKLA Lapsed